US20040194793A1 - Coated nicotine-containing chewing gum, manufacture and use thereof - Google Patents

Coated nicotine-containing chewing gum, manufacture and use thereof Download PDF

Info

Publication number
US20040194793A1
US20040194793A1 US10/481,053 US48105304A US2004194793A1 US 20040194793 A1 US20040194793 A1 US 20040194793A1 US 48105304 A US48105304 A US 48105304A US 2004194793 A1 US2004194793 A1 US 2004194793A1
Authority
US
United States
Prior art keywords
nicotine
chewing gum
subject
coating
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/481,053
Inventor
Katarina Lindell
Nils-Olof Lindberg
Roland Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McNeil AB
Original Assignee
Pharmacia AB
McNeil AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB, McNeil AB filed Critical Pharmacia AB
Assigned to PHARMACIA AB reassignment PHARMACIA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LINDBERG, NILS-OLOF, LINDELL, KATARINA, OLSSON, ROLAND
Publication of US20040194793A1 publication Critical patent/US20040194793A1/en
Assigned to MCNEIL AB reassignment MCNEIL AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PFIZER HEALTH AB, PHARMACIA AB
Priority to US13/249,619 priority Critical patent/US20120017924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
    • A23B4/00General methods for preserving meat, sausages, fish or fish products
    • A23B4/10Coating with a protective layer; Compositions or apparatus therefor
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/02Apparatus specially adapted for manufacture or treatment of chewing gum
    • A23G4/04Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping
    • A23G4/043Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping for composite chewing gum
    • A23G4/046Apparatus specially adapted for manufacture or treatment of chewing gum for moulding or shaping for composite chewing gum with a centre made of chewing gum
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G4/126Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/18Chewing gum characterised by shape, structure or physical form, e.g. aerated products
    • A23G4/20Composite products, e.g. centre-filled, multi-layer, laminated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a coated chewing gum product for delivering nicotine to a subject. Also contemplated is a method and a system for delivering nicotine as well as use and production of said coated chewing gum product
  • Nicotine is an organic compound and is the principal alkaloid of tobacco. Nicotine is the chief addictive ingredient in the tobacco used in cigarettes, cigars, snuff and the like. Nicotine is also an addictive drug, though, and smokers characteristically display a strong tendency to relapse after having successfully stopped smoking for a time. Nicotine is the worlds second most used drug, after caffeine from coffee and tea.
  • the administration of nicotine can give satisfaction and the usual method is by smoking, either by smoking e.g., a cigarette, a cigar or a pipe.
  • smoking has health hazards and it is therefore desirable to formulate an alternative way of administering nicotine in a pleasurable manner that can be used to facilitate withdrawal from smoking and/or used as a replacement for smoking.
  • Nicotine is an addictive poisonous alkaloid C 5 H 4 NC 4 H 7 NCH 3 , derived from the tobacco plant. Nicotine is also used as an insecticide. Approximately forty milligrams of nicotine is able to kill an adult (Merck Index).
  • Nicotine containing formulations are currently the dominating treatments for tobacco dependence.
  • Nicotine-containing nose drops have been reported (Russell et al., British Medical Journal, Vol. 286, p. 683 (1983); Jarvis et al., Brit. J. of Addiction, Vol. 82, p. 983 (1987)). Nose drops, however, are difficult to administer and are not convenient for use at work or in other public situations. Ways of administrating nicotine by way of delivering directly into the nasal cavity by spraying is known from U.S. Pat. No. 4,579,858, German Patent No. 32 41 437 and International Publication No. WO/9312764. There may, though, be local nasal irritation with use of nasal nicotine formulations. The difficulty in administration also results in unpredictability of the dose of nicotine administered.
  • inhaling devices resembling a cigarette are known for uptake of nicotine vapours as suggested in U.S. Pat. No. 5,167,242. Said means and methods address the problems associated with addiction to nicotine.
  • Nicorette® One successful product that is used as a smoking substitute and/or as a smoking cessation aid and which is based on nicotine, is the chewing gum Nicorette®.
  • This product was one of the first nicotine replacement forms that was approved by the Food and Drug Administration (FDA) and is still one of the most used nicotine replacement products.
  • Nicorette® chewing gum has been on the market in about 60 countries for several years. In this chewing gum the nicotine is present in the form of a complex with an insoluble cation-exchanger (polacrilex) that is dispersed in a gum base. The nicotine is slowly released from the gum due to chewing and will reach similar plasma levels as when smoking a cigarette after about 30 minutes depending on the chewing technique, i.e., slow or active.
  • Patents related to this product are, e.g., the U.S. Pat. Nos. 3,877,468, 3,901,248 and 3,845,217.
  • WO 98/23165 discloses a chewing gum wherein nicotine may be in the coating. This concept may provide rapid release of the nicotine from the coated chewing gum, but not a sufficiently rapid buccal uptake of the nicotine. The fraction of the released nicotine that is not immediately absorbed will be flushed down in the gastrointestinal (G.I.) tracts by the saliva, thereby possibly causing hiccups and other G.I. side effects. Once absorbed by the G.I. route this swallowed nicotine will be subjected to first pass metabolism.
  • G.I. gastrointestinal
  • WO 00/13662 discloses a chewing gum for systemic, oral administration of an active whereby said active is administered by the chewing gum composition in a bi-phasic manner.
  • the bi-phasic delivery is obtained by the gum matrix as such, not from any coating.
  • WO 00/19977 discloses a substantially moisture free and possibly coated chewing gum for delivery of an active. The possible coating is not said to be buffered.
  • the present invention provides a new and improved product, systems and methods for obtaining a rapid transmucosal uptake of nicotine in the oral cavity of the subject.
  • An object of the present invention is to provide an efficient and effective product, as well as methods and systems for a rapid uptake of nicotine in a subject to avoid the disadvantages of such previously known products and methods.
  • the present invention provides a method for delivering nicotine in any form to a subject comprising administering to a subject said coated chewing gum product containing nicotine in any form into the oral cavity of the subject and allowing the nicotine in any form in the coated chewing gum product to be released in the saliva in the oral cavity and absorbed into the systemic circulation of the subject as well as a method for producing said coated chewing gum.
  • the present invention also provides a method for obtaining reduction of the urge to smoke or use tobacco containing material and/or for providing a sense of smoking satisfaction without smoking, comprising the steps of replacing at least partly the tobacco containing material with above said coated chewing gum product, administering to a subject a coated chewing gum product containing nicotine in any form into the oral cavity of the subject and allowing the nicotine in any form of the coated chewing gum product to be released in the saliva in the oral cavity and absorbed by the subject.
  • the present invention provides a system for delivering nicotine in any form to a subject, comprising said coated chewing gum product and at least one other means for obtaining reduction of the urge to smoke or use of tobacco as well as a system for obtaining reduction of the urge to smoke or otherwise use of tobacco and/or for providing a sense of smoking satisfaction without smoking, comprising a coated chewing gum product according to above and at least one other method for obtaining reduction of the urge to smoke or otherwise use of tobacco.
  • Said system may be a system wherein the at least other method is selected from the group consisting of administration through mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets and parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods and transmucousal methods; or otherwise use of tobacco.
  • the present invention relates to a coated chewing gum product comprising at least one chewing gum core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additive, wherein said at least one coating layer is buffered.
  • Said product may further comprise at least one core being buffered and further may also the nicotine in any form be a part of the at least one coating layer or at least one of the at least one coating layers.
  • the at least one coating is buffered, according to the invention, in such a way that upon administration of the gum the pH of the saliva is increased by 0.3-4 pH units, or preferably increased by 0.5-2 pH units.
  • Said product is buffered by the use of a buffer selected from the group consisting of a carbonate, including bicarbonate or sesquicarbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, such as potassium and sodium, e.g., trisodium and tripotassium citrate, or ammonium, and mixtures thereof.
  • a buffer selected from the group consisting of a carbonate, including bicarbonate or sesquicarbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, such as potassium and sodium, e.g., trisodium and tripotassium citrate, or ammonium, and mixtures thereof.
  • Use of said product will according to the invention rapidly deliver nicotine in any form to a subject and will also be used for obtaining a quick and/or sustained and/or complete reduction of the urge to smoke or use tobacco and/or for providing a sense of smoking satisfaction without smoking resembling the sense of smoking satisfaction and reduction of the urge to smoke obtained after regular smoking or use of tobacco.
  • chewing gum product intends to mean all chewable gum products.
  • fast reduction of the urge to smoke or use tobacco is herein intended to mean an initial priming of the subject so as to achieve a reduction of the urge to smoke or use tobacco.
  • sustained is herein intended to mean prolonged over time.
  • controlled release is intended to mean a release of a substance from a gum by the aid of active chewing of the gum in the oral cavity of the subject, whereby the active chewing is controlling the amount of substance released.
  • slow release is intended to mean that the nicotine is released from the gum upon, e.g., chewing, over a period of time e.g., several minutes to an hour.
  • unit formula is intended to mean one chewing gum product.
  • transient is intended to mean a non-permanent change, upon which the relevant state, e.g., biological or physiological state, after a certain period of time will return to its value or behaviour prior to said change.
  • the present invention relates to a coated chewing gum product for improving the absorption of nicotine in a subject, and wherein the absorption is quicker than by using current means and methods known in the art of nicotine chewing gums.
  • Such a rapid transmucosal uptake of the nicotine in the oral cavity is expected to give more of a cigarette like sense of satisfaction and a more rapid reduction of the urge to smoke and use tobacco.
  • a coated chewing gum product is used for improving the absorption of said nicotine.
  • the coated chewing gum product comprises at least one chewing gum core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and at least one other additive, wherein at least one of said coating layer is buffered.
  • the at least one core may be buffered in different embodiments.
  • the core may be buffered with the same or different ways of buffering as the at least one coating layer.
  • Said buffering of the at least one coating layer and optionally the at least one core generates a coated chewing gum product giving improved absorption kinetics of nicotine compared to in the art known chewing gum products.
  • the chewing gum product may be a medicated chewing gum.
  • Medicated chewing gums are herein intended to mean solid or semi-solid, single-dose preparations with a base consisting mainly of gum that are intended to be chewed but not swallowed, where the chewing gums act as a drug delivery system. They contain one or more active substances, which are released by chewing. After dissolution or dispersion of the active substance in the saliva, such chewing gums are used for i) local treatment of mouth diseases and ii) systemic delivery after absorption through transmucosal uptake throughout the oral cavity.
  • the coated chewing gum product is buffered. This may be achieved by including physiologically acceptable buffering substances or agents, or by other means. With other means it is intended to include buffering by any component in the product, which may not normally act as a buffering agent, such as a self-buffering additive or gum base.
  • At least one coating layer is buffered.
  • also the at least one core is buffered.
  • the at least one coating layer is buffered in such a way that upon administration of the gum the pH of the saliva is increased 0.3-4 pH units, preferably 0.5-2 pH units.
  • the buffering is designed so as to achieve a transient buffering of the saliva of a subject during melting, disintegration or dissolution of the coating layer or layers. As the change is transient, the pH will return to its normal value after a certain period of time.
  • the at least one core may be buffered. This may allow said change in the pH to be ensured during chewing of the core of the gum product, where the chewing allows the suitable buffer agent or substance or other means to produce a transient change in the pH of the saliva, e.g., an increase in the pH.
  • the transmucosal uptake of nicotine in the oral cavity is changed, e.g., increased compared to the nicotine uptake when the saliva is not buffered according to the invention.
  • the transmucosal uptake of nicotine in the oral cavity according to the invention is faster than for nicotine not being buffered according to the invention, less nicotine will be swallowed to reach the gastrointestinal (G.I.) tract.
  • the nicotine that reaches the G.I. tract will be subjected to first pass metabolism which reduces the total amount of intact nicotine absorbed. This means that the bio-availability of nicotine that is not co-administered with a buffer according to the invention will generally be lower than when administered together with a buffer.
  • Further embodiments of the invention includes combinations wherein the at least one coating layer is buffered by the use of a buffer selected from the group consisting of a carbonate including bicarbonate or sesquicarbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, such as potassium or sodium, or ammonium, and mixtures thereof.
  • a buffer selected from the group consisting of a carbonate including bicarbonate or sesquicarbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, such as potassium or sodium, or ammonium, and mixtures thereof.
  • Further embodiments may use trisodium or tripotassium citrate, and mixtures thereof.
  • Still further embodiments may use different phosphate systems, such as trisodium phosphate, disodium hydrogen phosphate; and tripotassium phosphate, dipotassium hydrogen phosphate, and calcium hydroxide, sodium glycinate; and mixtures thereof.
  • phosphate systems such as trisodium phosphate, disodium hydrogen phosphate; and tripotassium phosphate, dipotassium hydrogen phosphate, and calcium hydroxide, sodium glycinate; and mixtures thereof.
  • Alkali metal carbonates, glycinates and phosphates are preferred buffering agents.
  • the one or more buffering agents may to some extent be microencapsulated or otherwise coated as granules with polymers and/or lipids being less soluble in saliva than is the one or more buffering agents. Such microencapsulation controls the dissolution rate whereby is extended the time frame of the buffering effect.
  • a second or auxiliary buffering agent to the first buffering agent, such as e.g., sodium or potassium bicarbonate buffers.
  • the second or auxiliary buffering agent may be selected from the group consisting of alkali metal bicarbonates that are preferred for this purpose.
  • further embodiments of the invention may comprise a mixture of an alkali metal carbonate or phosphate and alkali metal bicarbonate.
  • the amount of the buffering agent or agents in the chewing gum composition is preferably sufficient in the specific embodiments to raise the pH of the saliva to above 7, as specified above, to transiently maintain the pH of the saliva in the oral cavity above 7, e.g., pH 7-11.
  • the nicotine may be administered in different forms, e.g., in different complexes or salts.
  • the amount of buffer required to achieve such an increase in pH of the different administered nicotine form is readily calculated by the skilled man in the art. The extent and duration of the increase in pH is dependent on type and amount of the buffering agent(s) used as well as where, i.e., in the at least one coating layer and optionally in the at least one core, the buffer is distributed in the product and is further described within the paragraphs below.
  • the process of coating a chewing gum is well known in the art.
  • the present invention provides a coating, to facilitate the uptake of administered nicotine in any form to the subject.
  • Known intentions of coating a chewing gum product may be to add crispiness, enhance taste, or to protect the gum, e.g., during storage, or as to tone down bad or irritating taste of the gum product.
  • the chewing gum is a coated chewing gum comprising at least one coating layer.
  • the different embodiments according to the invention may use sugar coating, film coating, press/compression coating or melt coating.
  • the coating procedure may be manual or the coating may be sprayed onto the gum core/pellet in rotating pans of different shapes or fluidised beds in combination with evaporation of the solvent, e.g., water or organic solvent.
  • the solvent e.g., water or organic solvent.
  • Sugar coating is a multistep process and may be divided into the following steps: 1. sealing of the cores; 2. subcoating; 3. smoothing, or glossing; 4. colouring; 5. polishing; and 6. optionally printing
  • Sugar coated cores have a smoother profile with less visible edges remaining from the original core.
  • Sub-coating e.g., either by dusting with powder on the sucrose solution or application of dry powder in the sucrose solution, may be used.
  • the core may be sugar coated by a panning technique, e.g., using a sugar coating pan, or other more sophisticated techniques capable of some degree of automation.
  • the sugar in a sugar coating may not be just sucrose. Also other types of sugar may do as well, e.g., sugar alcohols (polyalcohol, polyol).
  • the sugar used in the sugar coating may according to specific embodiments also be an artificial sweetener, being low or substantially free of calories and less caries promoting than regular sugar, or a combination with sugar and/or sugar alcohol.
  • Film coating involves the deposition, usually by a spray method, of a thin film of polymer surrounding the core.
  • the solution may be sprayed on to a rotated, mixed bed.
  • the drying conditions permit the removal of the solvent so as to leave a thin deposition of coating material around each core.
  • composition of the coating solutions and suspensions may differ during different parts of the process.
  • Press coating involves the compaction of granular material around an already manufactured core. Using press/compression coating, a further core is pressed on the outside of the initial core/cores.
  • Example 1-4 describes four different coatings and coating compositions that may be used according to the invention, i.e., sugar coating in example 1, film coating in example 2, press coating in example 3 and melt coating in example 4, all onto a chewing gum core.
  • the coating is buffered in each case and contains nicotine as well.
  • the coatings in example 1-4 may be combined with different cores. Examples of cores are given in Example 5 and further described below.
  • NHT nicotine hydrogen tartrate
  • buffer are suitably separated from each other in the coating by keeping them in separate layers, especially when sugar coating is used.
  • a moisture barrier between the NHT-containing layer and the coating comprising the buffer may be applied to prevent interaction between the acid salt NHT and the buffer during the coating process. Suitable moisture barriers are e.g.
  • ethylcellulose or a combination of ethylcellulose and hydroxypropyl methylcellulose (HPMC) and/or plasticizer from an organic solvent or solvent mixture aqueous ethylcellulose dispersion such as Aquacoat EDC (FMC Corp.) or Surelease (Colorcon) preferably in combination with plasticizer, Sepifilm LP 007 or LP 010 (Seppic)—based mainly on HPMC and stearic acid—, Opadry AMB or High Performance Opadry II (Colorcon)—based mainly on polyvinylalcohol—, and polymethacrylates as Eudragit L30 D-55 or EPO (Röhm).
  • the moisture barrier preferably accounts for a weight of around 0.3% to around 5% of the total weight of the coating.
  • An additive may be added to the coating or the core/s. Additives are further described in the paragraph entitled “Other additives to the chewing gum”.
  • the amount of gum base in the coated chewing gum according to the invention is about 15-80% by weight of the total gum core, and preferably at least about 40%.
  • the amount of gum base employed for the most desirable slow release of nicotine is usually in the higher ranges when nicotine is employed per se or when an absorbed form is used.
  • the gum base may be of any conventional nature known in the art.
  • it may comprise a gum base of natural or synthetic origin readily available from a commercial source.
  • Natural gum bases include, e.g., chicle, jelutong-, lechi de caspi-, soh-, siak-, katiau-, sorwa-, balata-, pendare-, malaya-, and peach gums, natural cautchouc and natural resins such as dammar and mastix.
  • Synthetic gum bases are a mixture of:
  • plasticizer resin, elastomers, solvent, hydrophobic resin
  • filler texturizer, water-insoluble adjuvant
  • anti-tacking agents vinyl polymer, hydrophilic resin.
  • gum bases include agar, alginate, arabic gum, carob gum, carrageenan, ghatti gum, guar gum, karaya gum, pectin, tragacanth gum, locust beam gum, gellan gum and xanthan gum.
  • gelling agents comprise gum arabic, starch, gelatine, agar, and pectin.
  • the nicotine in any form and the buffering agent or agents are incorporated in the chewing gum mass in accordance with the present invention, it is possible to employ a wide variety of chewing gum compositions and amounts of the chewing gum base. Different chewing gum products may be composed depending on the consumers preference and the purpose of use, in respect of the nicotine level, nicotine distribution and other additives.
  • the chewing gum product comprises nicotine in any form and/or a nicotine mimicking agent.
  • the nicotine is part of the at least one coating layer or at least one of the at least one coating layers.
  • the nicotine is a part of the chewing gum core or at least one of the chewing gum cores.
  • the nicotine is part of the at least one coating layer or at least one of the at least one coating layers and the chewing gum core or at least one of the chewing gum cores to give a fast transmucosal uptake of the nicotine in the oral cavity of a subject so as to obtain a rapid kick or reduction of the urge to smoke and/or use tobacco. Thereby may also be achieved a systemic maintenance level of nicotine.
  • the nicotine should be in a saliva soluble form to facilitate the release of the agent into the saliva in the oral cavity and, further, the subsequent uptake of the nicotine from the saliva in the oral cavity into the systemic circulation of the subject.
  • the nicotine in any form is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine inclusion complex or nicotine in any non-covalent binding; nicotine bound to zeolites; nicotine bound to cellulose or starch microspheres; and mixtures thereof.
  • the inclusion complex may be a cyclodextrin, such as ⁇ -cyclodextrin.
  • the cation exchanger may be a polyacrylate.
  • the nicotine salt may be a tartrate, hydrogen tartrate, citrate or malate.
  • the uptake of the nicotine through any tissue or mucosa in the oral cavity i.e., the absorption kinetics
  • the uptake obtained by known chewing gum products for nicotine uptake is improved in relation to the uptake obtained by known chewing gum products for nicotine uptake.
  • the nicotine may act as a stimulant to e.g., obtain a rapid reduction of the urge to smoke or to use tobacco.
  • nicotine it is intended to include nicotine, 3-(1-methyl-2-pyrrolidinyl)-pyridine, with its base form, including synthetic nicotine as well as nicotine extracts from tobacco plants, or parts thereof, such as the genus Nicotiana alone or in combination; or pharmaceutically acceptable salts.
  • the most preferable embodiment incorporates nicotine as the free base form or as a water-soluble pharmaceutically acceptable salt, either per se or adsorbed on a adsorbent, or as a complex with a cation exchanger or mixtures of the foregoing, as an inclusion complex, such as a cyclodextrin complex, e.g., ⁇ -cyclodextrin, but any other suitable pharmaceutically acceptable form may also be employed.
  • a cyclodextrin complex e.g., ⁇ -cyclodextrin, but any other suitable pharmaceutically acceptable form may also be employed.
  • the product according to the invention may also comprise a nicotine mimicking agent.
  • a nicotine mimicking agent may be any suitable agent with an acrid burning taste.
  • nicotine mimicking agents with an acrid burning taste are capsaicin, piperine and zingerone.
  • additives may be added to the coating or the core/s. Additives are further described in the paragraph entitled “Other additives to the chewing gum”.
  • the nicotine in any form is according to the invention formulated to provide the subject with a dose to achieve an effect.
  • the effect may be to provide a sense of smoking satisfaction without smoking.
  • Another effect of the administered nicotine in any form may be a reduction of the urge to smoke or use tobacco.
  • the effect may also be a combination of reduction of said urge and providing a sense of smoking satisfaction without smoking.
  • the amount of the nicotine should be sufficient to provide such an effect in a subject. This amount may, of course, vary from person to person.
  • embodiments of the chewable gum product comprise embodiments wherein nicotine in any form is present in an amount of 0.05-10 mg calculated as the free base form of nicotine per piece coated chewing gum product.
  • This may in different embodiments include 0.05, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg calculated as the free base form of nicotine per piece coated chewing gum product.
  • Still preferred embodiments may contain embodiments where the nicotine in any form is present in an amount of 0.5-6 mg calculated as the free base form of nicotine per piece coated chewing gum product.
  • Even more preferred embodiments contain the nicotine in any form in an amount of 0.5-4 mg calculated as the free base form of nicotine per piece coated chewing gum product.
  • the nicotine in any form is part of the at least one coating layer or at least one of the at least one coating layer.
  • the nicotine in any form may be in an amount of 0-10 mg calculated as free base form in at least one of the at least one coating layer. Still further embodiments comprise nicotine in an amount of 0.2-6 mg in at least one of the at least one coating layers, or even more preferably, in an amount of 0.5-5 mg in at least one of the at least one coating layer.
  • the nicotine in any form may be distributed in the core and/or different coating layers in different embodiments. Different distributions of the nicotine throughout the coated chewing gum will imply administration of the nicotine to the subject in different ways. This may, then, provide several possibilities to adjust the composition of the coated chewing gum according to different needs of different subjects depending on the urge to smoke or use tobacco of the subject.
  • t max i.e., the time-point where the nicotine has its maximum level measured in the plasma of venous blood, after a single dose at about 30 minutes after administration.
  • the t max is initially preceded by a lag period of a couple of minutes where no nicotine can be detected in the blood. Then, the plasma level is gradually increasing till the t max is reached.
  • the time point for reaching a sense of satisfaction or reduction of urge to smoke or use tobacco after the initial lag period is individual, but may in existing chewing gums generally be reached after approximately 30 minutes when regarded as coinciding with t max . According to the present invention, such a sense of satisfaction may be reached after a shorter period of time due to a rapid initial burst dose of nicotine in the coating followed by a rapid transmucosal uptake in the oral cavity due to the buffered coating.
  • the release of the nicotine in the coated chewing gum according to the invention proceeds in at least one step.
  • the nicotine is, as in preferred embodiments, in a defined amount, such as the amounts described above according to different embodiments, in at least one of the at least one coating layers defined above the release of the nicotine takes place when the coating of the coated chewing gum is allowed to melt, disintegrate or dissolve to uncover the chewable gum core in said product.
  • the nicotine and forms thereof is released from the coating into the saliva in the oral cavity during the time period when the coating is allowed to melt, disintegrate or dissolve.
  • the at least one coating layer is allowed to melt, disintegrate or dissolute a chewable gum is uncovered.
  • the nicotine in any form may then further be released to the subject.
  • the nicotine in any form from the chewable gum is released by controlled release, e.g., by chewing the gum core whereby the chewing is controlling the amount of released nicotine from the gum core.
  • the release of the nicotine is thereby sustained over a period of time. This period of time may be, in different embodiments about 10, 20, 30, 40, 50, or 60 minutes.
  • the dissolution of the one or more buffering agents in the coating, and optionally in the core(s), provides for optimized adjustment of the pH of the liquid in the oral cavity.
  • the release may be varied by the incorporation of the nicotine in any form in a given quantity into the coating layers and/or the gum core.
  • Suitable cat ion exchangers are given in table 2 and are further disclosed in U.S. Pat. No. 3,845,217, hereby included as a reference.
  • Preferred are nicotine cation exchangers of polyacrylates, such as the Amberlite collection from Rohm & Haas in table 2. Examples of different salts are given in Table 1.
  • TABLE 2 Representative cation exchangers Name Manufacturer Amberlite IRC 50 Rohm & Haas Amberlite IRP 64 Rohm & Haas Amberlite IRP 64M Rohm & Haas BIO-REX 70 BIO-RAD Lab.
  • Duolite ES-63 Chemical Process Duolite ES-65 Chemical Process Ohelex 100 BIO-RAD Lab.
  • Dow Chelating Resin A-1 Dow Chemical Company Purolite C115HMR Purolite International Ltd.
  • CM Sephadex C-25 Pharmacia Fine Chemicals SE Sephadex C-25 Pharmacia Fine Chemicals
  • the amount of the nicotine released from the different parts of the chewing gum product is of value as known in the art, but also, according to the present invention the specific transmucosal uptake from the oral cavity of the nicotine to the systemic circulation of the subject whereby the one or more buffering agents account for provision of a suitable adjustment of the pH of the liquid of the oral cavity.
  • the uptake according to the invention is further discussed in the method paragraphs below.
  • additives may be added optionally to the chewing gum core and/or to coating layers in the chewing gum.
  • Optional additives comprise at least one or more additive selected from the group consisting of stabilisers, such as preservatives, e.g., antioxidants; softeners, thickening agents, emulsifiers, glidants, lubricants, sweeteners, flavours, aromatics, enhancers, colouring agents, vitamins, minerals, fluorine and tooth whitening agents and mixtures thereof.
  • additives such as preservatives, e.g., antioxidants; softeners, thickening agents, emulsifiers, glidants, lubricants, sweeteners, flavours, aromatics, enhancers, colouring agents, vitamins, minerals, fluorine and tooth whitening agents and mixtures thereof.
  • at least one of such additives is optionally added to the product.
  • Enhancers are added essentially to improve, i.e., increase, the transmucosal uptake from the oral cavity.
  • Sweeteners are added essentially to improve the taste.
  • Sweeteners comprise one or more synthetic or natural sugars, i.e., any form of carbohydrates suitable for use as sweetener, as well as so called artificial sweeteners such as saccarin, sodium saccarin, aspartame, e.g., NutraSweet®, acesulfame K or acesulfame, potassium acesulfame, thaumatin, glycyrrhizin, sucralose, dihydrochalcone, alitame, miraculin, monellin, stevside.
  • artificial sweeteners such as saccarin, sodium saccarin, aspartame, e.g., NutraSweet®, acesulfame K or acesulfame, potassium acesulfame, thaumatin, glycyrrhizin, sucralose, dihydrochalcone, alitame, miraculin, monellin, stevside.
  • Suitable sweeteners may be selected from the group consisting of sugar alcohols, such as sorbitol, xylitol, single sugars including sugars extracted from sugar cane and sugar beet (sucrose), dextrose (also called glucose), fructose (also called leavulose), and lactose (also called milk sugar); sorbitol, mannitol, glycerol, xylitol, maltitol syrup (or hydrogenated starch hydrolyzate), isomalt, lactitol; and mixtures of sugars including glucose syrup, e.g., starch hydrolysates, containing a mixture of dextrose, maltose and a range of complex sugars, invert sugar syrup, e.g., sucrose inverted by invertase (also called sucrase or sacchrase) containing a mixture of dextrose and fructose, high sugar content syrups such as treacle and honey containing a
  • flavour and aroma additives may comprise one or more synthetic or natural flavouring or aromatizing agents.
  • Flavour and aroma agents may be selected from essential oils including distillations, solvent extractions, or cold expressions of chopped flowers, leaves, peel or pulped whole fruit comprising mixtures of alcohols, esters, aldehydes and lactones; essences including either diluted solutions of essential oils, or mixtures of synthetic chemicals blended to match the natural flavour of the fruit, e.g., strawberry, raspberry and black currant; artificial and natural flavours of brews and liquors, e.g., cognac, whisky, rum, gin, sherry, port, and wine; tobacco, coffee, tea, cocoa, and mint; fruit juices including expelled juice from washed, scrubbed fruits such as lemon, orange, and lime; spear mint, pepper mint, wintergreen, cinnamon, cacoe/cocoa, vanilla, liquorice, menthol, eucalyptus, aniseeds nuts (e.g., peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts), almonds, raisins;
  • Colouring additives may be selected from dyes being approved as a food additive.
  • Stabilizing additives may be selected from the group consisting of antioxidants including vitamin E, i.e., tocopherole, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid and edetate salts; and preservatives including citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid.
  • Preferred embodiments comprise an antioxidant as the stabiliser, and even more preferably the antioxidant vitamin E and/or butylated hydroxytoluene (BHT).
  • a method for delivering nicotine in any form to a subject comprises the steps of
  • the transmucosal uptake of the nicotine in the oral cavity is more rapid than with presently known chewing gum not being buffered in the coating.
  • One embodiment results in a t max of nicotine in venous blood of the subject after about 5-20 minutes.
  • said nicotine in any form is absorbed resulting in a t max of nicotine in venous blood of the subject after about 3-15 minutes.
  • the method for delivering nicotine in any form may further comprise the steps of
  • Such a time period may be at least 10, 20, 30, 40, 50 or 60 minutes.
  • a method for obtaining reduction of the urge to smoke or use tobacco containing material and/or for providing a sense of smoking satisfaction without smoking comprises the steps of
  • said nicotine in any form results in a t max of nicotine in venous blood of the subject after about 5-20 minutes.
  • the absorbing of said nicotine released from the at least one coating layer is resulting in a t max of nicotine in venous blood of the subject after about 3-15 minutes.
  • the method according to the invention further comprises the steps of administering the nicotine in any form in a sustained way over a period of time to the subject.
  • the period of time may be at least 10, 20, 30, 40, 50 or 60 minutes.
  • Yet further embodiments of the method for delivering nicotine to a subject may comprise the steps of combining at least one other method for obtaining reduction of the urge to smoke or use of tobacco.
  • Tobacco containing material may be material used for e.g., smoking, snuffing or chewing and may comprise a cigarette, a cigarr, snuff, pipe tobacco and also chewing tobacco.
  • the coated chewing gum product may be used for obtaining a quick and/or sustained and/or complete reduction of the urge to smoke or use of tobacco and/or for providing a sense of smoking satisfaction without smoking as further discussed below.
  • the fast relief provides the subject with a sense of rapid smoking satisfaction without smoking. Such a satisfaction will decrease the craving more rapidly than other known nicotine chewing gum products.
  • the quick craving relief is obtained when a dosage of nicotine is released from at least one of the at least one coating layers of the coated chewing gum in embodiments wherein nicotine is in the coating layers in the presence of one or more buffering agents in the coating and optionally in the core(s).
  • This provides the subject with an initial rapid transmucosal uptake of nicotine in the oral cavity that will induce an initial peak, a maximum, in the blood plasma nicotine levels after a certain time, t max .
  • the result will be that the subject gets a feeling or sense of satisfaction and the initial craving will disappear.
  • One embodiment reduces the urge to smoke or use of tobacco by reaching a t max of nicotine in venous blood of the subject after about 5-20 minutes by the use of a coated chewing gum according to the invention.
  • Still one embodiment reduces the urge to smoke or use of tobacco quickly resulting in a t max of nicotine in venous blood of the subject after about 3-15 minutes when said nicotine in any form is released from the at least one coating layer after use of a coated chewing gum according to the invention.
  • a sustained craving relief may be obtained after the initial craving relief.
  • a sustained craving relief is obtained by chewing the gum part, or core, of the coated chewing gum to allow a sustained uptake of the nicotine.
  • the sustained craving relief and/or feeling or sense of satisfaction of the subject will continue as long as the subject maintains the blood plasma levels of nicotine at a level high enough to reach this sense of feeling.
  • the subject may achieve this by chewing the gum part of the chewing gum over a period of time, such as 10, 20, 30, 40, 50, or even 60 minutes or longer, e.g., a slow release of the nicotine caused by a controlled release, e.g., by individual chewing.
  • the method described above for obtaining craving relief may further comprise the steps of decreasing the amount of nicotine in the total coated chewing gum product described above gradually over time, so as to achieve a complete relief of tobacco craving. This method results in a weaning process gradually over time.
  • Different types of smokers reach the sense of reduced craving at different plasma levels of nicotine. This may, of course, affect the individual types of administration programs of a coated chewing gum according to the invention.
  • Different types of smokers include e.g., peak seekers or smokers that crave for a plasma level of nicotine constantly being above the level for withdrawal symptoms.
  • One strategy may be to lower the frequency of the administered coated chewing gums.
  • Other embodiments include varying the dose of the nicotine in said gums as well as the combination of these two.
  • the strategy may include a coated chewing gum with substantially no nicotine in any form. Such a gum may be administered at the end of the treatment period, when the craving is low or substantially absent.
  • a system for delivering nicotine in any form to a subject comprises a coated chewing gum according to the invention and at least one other means for obtaining reduction of the urge to smoke.
  • Another system according to the invention may also be a system for obtaining reduction of the urge to smoke or use of tobacco and/or for providing a sense of smoking satisfaction without smoking.
  • a system comprises a coated chewing gum product according to the invention and at least one other method for obtaining reduction of the urge to smoke or use tobacco.
  • Other methods may also be a concomitant or concurrent method selected from the group consisting of administration through mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets and parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods and transmucosal methods; or use of tobacco.
  • the at least other method comprises administration of nicotine.
  • the use of the coated chewing gum product according to the invention is for obtaining a fast and/or sustained and/or complete reduction of the urge to smoke and use tobacco or for providing a sense of smoking without smoking as described above.
  • the dose of the nicotine is chosen to give the subject an individual sensory perception and satisfaction with an effect of the nicotine in any form.
  • the use of the coated chewing gum product may also be a sole use according to the invention or a combination with other means or methods known in the field of drug abuse. Specifically, the present invention may be used in combination with other means as described above in the methods in the paragraphs above.
  • the use may give a quick reduction of the urge to smoke or use tobacco obtained reaching a t max of nicotine in venous blood after e.g., about 5-20 minutes.
  • the use of the coated chewing gum according to the invention will reduce the urge to smoke or use tobacco by reaching a t max , of nicotine in venous blood of the subject after about 3-15 minutes when said nicotine in any form is released from the at least one coating layer.
  • a use of a coated chewing gum product according to the invention is also disclosed for delivering nicotine in any form to a subject.
  • the delivering of nicotine in any form results in a t max of nicotine in venous blood of the subject after about 5-20 minutes.
  • the delivering of nicotine in any form results in a t max of nicotine in venous blood of the subject after about 3-15 minutes when said nicotine in any form released from the at least one coating layer is absorbed.
  • Coated chewing gum products according to the invention can be maintained in several production steps depending on the total number of cores and the total number of coated layers to be included.
  • the method comprises the steps of
  • the method may in specific embodiments further comprise
  • the nicotine is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine inclusion complex or nicotine in any non-covalent binding; nicotine bound to zeolites; nicotine bound to cellulose or starch microspheres; and mixtures thereof.
  • the at least one coating layer may in some embodiments be buffered by the use a buffer selected from the group consisting of a carbonate buffer, such as the carbonate, bicarbonate, sesquicarbonate of an alkali metal, e.g., potassium, sodium; or ammonium; sodium glycinate, alkali metal phosphate, sodium or potassium glycerophosphate, trisodium or tripotassium citrate, and mixtures thereof wherein the at least one coating layer is buffered in such a way that upon administration of the gum the pH of the saliva is increased by 0.3-4 pH units.
  • the buffering may be transient.
  • the at least one coating layer is buffered in such way that upon administration of the gum the pH of the saliva is increased by 0.5-2 pH units.
  • the core/pellet composition may be formed simply by mixing, rolling and scoring or compression of the chewing gum base with at least one of the forms of nicotine, e.g., the nicotine-ion exchanger complex, or the nicotine as a free base or a salt. Before adding any solid component, except for the gum base, it is desirable to grind and size the solid component first, to ensure good distribution.
  • the mixing is preferably conducted at a suitably elevated temperature depending on the viscosity of the gum core used. The increase in temperature decreases the viscosity of the gum and thereby enables the nicotine and other additives to be evenly and intimately distributed within the core/pellet of the chewing gum.
  • Example 5 describes the mixing, rolling and scoring as well as the compression of gum cores. In principle, this procedure may be applied for coated chewing gum products up to at least 10 mg unit formula.
  • the gum is extruded into a thick sheet, which is rolled by multiple sets of calender rolls to the correct thickness.
  • the scoring rolls usually two sets, cut the gum into the correct size.
  • the sheets are then transferred to a conditioned area on trays, where the sheets are cooled to make them brittle enough to be broken.
  • the conditioned gum sheets are then passed through a breaker, which is a rotating drum that parts the sheets into separate pieces of gum along the scores.
  • Chewing gums produced by compression i.e., tabletted gums are made out of a special gum base. Such a gum base gives a rapid hydration of the cud in the mouth. High velocity mixers can be used for granulation to give correctly sized particles of the mixture. This mixture is then compressed in a tablet machine.
  • the provision of the at least one chewing gum core in step a) above comprises the further steps of
  • the provision of the chewing gum core in step a) is obtained by direct compressing of the ingredients.
  • compositions of additives according to the invention are made simultaneously, according to known procedures in the art for formulating the buffers.
  • the buffer system it may be convenient to add the buffer system/s either with the liquid part or with he solid part of the composition.
  • buffering systems available as fine powders, it may, of course, be most convenient to add those powders with the solid, powdered part of other additives.
  • the coating of the at least one chewing gum core with at least one layer of the at least one buffered coating comprises the steps of
  • the product may then be analysed and further wrapped.
  • the coated chewing gum product according to the invention may be used in therapy.
  • Said therapy may be a treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control.
  • the nicotine may also be used for the production of a chewing gum product according to the invention for the treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control.
  • a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control.
  • a chewing gum product for the production of a nicotine containing chewing gum product according to the invention for the treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, and ulcerous colitis.
  • the analysis of nicotine uptake and effect according to the invention may be done according to standard procedure known in the art, e.g., using a bioanalys for the determination of nicotine or its metabolites in the plasma of a subject.
  • This example describes without limiting the invention a sugar coating, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the objective of this example is to provide a sugar coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the nicotine is in the amount of 1, 2, 4 or 5 mg, respectively.
  • This example describes without limiting the invention a film coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the objective of this example is to provide a film coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the nicotine is in the amount of 1, 2, 4 or 5 mg, respectively.
  • This example describes without limiting the invention a press coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the objective of this example is to provide a press coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the nicotine is in the amount of 1, 2, 4 or 5 mg, respectively.
  • NRC or NCC 2 mg unit 4 mg unit formula (mg) Component NRC NCC NRC NCC Xylitab 100 a 727 720 717 703 HPMC, 3cPs 238 238 238 Sodium carbonate 15 15 30 30
  • NCC — 17.1 — 34.2 (corresponding to — 2 — 4 nicotine free base)
  • This example describes without limiting the invention a melt coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the objective of this example is to provide a melt coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating.
  • the nicotine is in the amount of 1, 2, 4 or 5 mg, respectively.
  • NHT 1 mg unit 2 mg unit 4 mg unit 5 mg unit Component formula formula formula formula formula formula Hydrogenated 176 176 176 176 176 176 vegetable oil, type II, (Akopol E) Cocoa, alkalized 198 197 192 191 Aspartame 2.4 2.4 2.4 2.4 Sodium carbonate 15 20 30 40 Lecithin 4 4 4 4 Nicotine hydrogen 3.1 6.2 12.3 15.4 tartrate, (corresponding to 1 2 4 5 nicotine base, mg)
  • the objective of this example is to provide a core suitable for a chewing gum product according to the invention.
  • the nicotine is incorporated as the free base (NFB), nicotine ⁇ -cyclodextrin complex (NCC), nicotine hydrogen tartrate (NHT) or as a nicotine resin complex (NRC).
  • the amount of nicotine in each fomula unit, i.e., per tablett core, is 1, 2, 4, or 6 mg.
  • the core is formed by a mixing, rolling and scoring process or by a compression process.
  • A. Manufactured by Tablet Compression Process 6 mg 4 mg 2 mg 1 mg unit formula unit formula unit formula unit formula (mg) (mg) (mg) (mg) Active ingredients Nicotine resin complex 20% 30 20 10 5 Other ingredients Chewing gum base for 500 500 500 500 compression a Xylitol 191 211 221 226 Sorbitol 100 100 100 100 100 100 100 100 Sodium carbonate anhydr. 40 30 20 10 Sodium bicarbonate — — 10 20 Magnesium stearate 15 15 15 15 15 Talcum 15 15 15 15 15 15 Magnesium oxide 5 5 5 5 5 Acesulfame K 2 2 2 2 Aspartame 2 2 2 2 2 2
  • the sheets are then transferred to a conditioned area on trays, where the sheets are cooled to make them brittle enough to be broken.
  • the conditioned gum sheets are then passed through a breaker, which is a rotating drum that parts the sheets into separate pieces of gum along the scores.
  • Chewing gums produced by compression i.e., tabletted gums are made out of a special gum base.
  • High velocity mixers can be used for granulation to give correctly sized particles of the mixture. This mixture is then compressed in a tablet machine.

Abstract

A coated chewing gum product for the delivering of nicotine in any form to a subject by a rapid transmucosal uptake in the oral cavity comprising at least one gum core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additive, wherein said at last one coating layer is buffered. Also contemplated is a method for the delivering of nicotine in any form, a method for the reduction of the urge to smoke or use tobacco as well as a method for producing said coated chewing gum and the use of the same form obtaining a quick transmucosal uptake of the nicotine in the oral cavity of a subject.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is the national stage filing under 35 U.S.C. § 371 of International Application No. PCT/SE02/01158 filed Jun. 14, 2002 and published Dec. 27, 2002, as International Publication No. WO 02/102357 which in turn claims priority under 35 U.S.C. § 119 to Swedish Patent Application No. 0102197, filed Jun. 20, 2001. The disclosures of these applications are incorporated herein by reference in their entirety.[0001]
  • FIELD
  • This invention relates to a coated chewing gum product for delivering nicotine to a subject. Also contemplated is a method and a system for delivering nicotine as well as use and production of said coated chewing gum product [0002]
  • BACKGROUND
  • Tobacco Dependence and Reduction Thereof. [0003]
  • In recent years, with the recognition of the harmful effects of tobacco smoking, there have been numerous campaigns and programs by governmental agencies and various health groups and other interested organisations to disseminate information about the adverse health effects resulting from tobacco smoking. Moreover, and as a result of this recognition of the harmful effects, there have been many programs directed to attempts in reducing smoking incidence. [0004]
  • Nicotine is an organic compound and is the principal alkaloid of tobacco. Nicotine is the chief addictive ingredient in the tobacco used in cigarettes, cigars, snuff and the like. Nicotine is also an addictive drug, though, and smokers characteristically display a strong tendency to relapse after having successfully stopped smoking for a time. Nicotine is the worlds second most used drug, after caffeine from coffee and tea. [0005]
  • The main problem with tobacco smoking is its enormous implications on health. Today it is estimated that smoking related diseases cause some 3-4 million deaths per year. In the US Surgeon General's 1988 report on The Health Consequences of Smoking, it was estimated that in the US alone about 300.000 deaths are caused each year by diseases related to cigarette smoking. In fact, excessive smoking is now recognised as one of the major health problems throughout the world. This grim consequence of tobacco smoking has urged many medical associations and health authorities to take very strong actions against the use of tobacco. [0006]
  • Even though tobacco smoking is decreasing in many developed countries today it is hard to see how the societies could get rid of the world's second most used drug. [0007]
  • The most advantageous thing a heavy smoker can do is to reduce or preferably even stop smoking completely. Experience shows, however, that most smokers find this extremely difficult since, mostly, tobacco smoking results in a dependence disorder or craving. The WHO has in its International Classification of Disorders a diagnosis called Tobacco Dependence. Others like the American Psychiatric Association call the addiction Nicotine Dependence. It is generally accepted that these difficulties to stop smoking result from the fact those heavy smokers are dependent on nicotine. The most important risk factors are, however, substances that are formed during the combustion of tobacco, such as carbon monoxide, tar products, aldehydes, and hydrocyanic acid. [0008]
  • Effects of Nicotine [0009]
  • The administration of nicotine can give satisfaction and the usual method is by smoking, either by smoking e.g., a cigarette, a cigar or a pipe. However, smoking has health hazards and it is therefore desirable to formulate an alternative way of administering nicotine in a pleasurable manner that can be used to facilitate withdrawal from smoking and/or used as a replacement for smoking. [0010]
  • When smoking a cigarette, nicotine is quickly absorbed into the smoker's blood and reaches the brain within around ten seconds after inhalation. The quick uptake of nicotine gives the consumer a rapid satisfaction, or kick. The satisfaction, then, lasts during the smoking time of the cigarette and for a period of time thereafter. The poisonous, toxic, carcinogenic, and addictive nature of smoking has provided efforts for methods, compositions and devices, which help in breaking the habit of smoking cigarettes. [0011]
  • Nicotine is an addictive poisonous alkaloid C[0012] 5H4NC4H7NCH3, derived from the tobacco plant. Nicotine is also used as an insecticide. Approximately forty milligrams of nicotine is able to kill an adult (Merck Index).
  • Nicotine Replacement Products [0013]
  • One way to reduce smoking is to provide nicotine in a form or manner other than by smoking and some products have been developed to fulfil this need. Nicotine containing formulations are currently the dominating treatments for tobacco dependence. [0014]
  • The successes in achieving reduction in the incidence of smoking have been relatively poor using presently known products. The present state of the art involves both behavioural approaches and pharmacological approaches. More than 80% of the tobacco smokers who initially quit smoking after using some behavioural or pharmacological approach to singly reduce smoking incidence generally relapse and return to the habit of smoking at their former rate of smoking within about a one year's period of time. [0015]
  • As an aid for those who are willing to stop smoking there are several ways and forms of nicotine replacement products available on the market; such as nicotine chewing gum. Several methods and means have been described for diminishing the desire of a subject to use tobacco, which comprises the step of administering to the subject nicotine or a derivative thereof as described in e.g., U.S. Pat. No. 5,810,018 (oral nicotine spray), U.S. Pat. No. 5,939,100 (nicotine containing microspheres) and U.S. Pat. No. 4,967,773 (nicotine containing lozenge). [0016]
  • Nicotine-containing nose drops have been reported (Russell et al., British Medical Journal, Vol. 286, p. 683 (1983); Jarvis et al., Brit. J. of Addiction, Vol. 82, p. 983 (1987)). Nose drops, however, are difficult to administer and are not convenient for use at work or in other public situations. Ways of administrating nicotine by way of delivering directly into the nasal cavity by spraying is known from U.S. Pat. No. 4,579,858, German Patent No. 32 41 437 and International Publication No. WO/9312764. There may, though, be local nasal irritation with use of nasal nicotine formulations. The difficulty in administration also results in unpredictability of the dose of nicotine administered. [0017]
  • The use of skin patches for transdermal administration of nicotine has been reported (Rose, in Pharmacologic Treatment of Tobacco Dependence, (1986) pp. 158-166, Harvard Univ. Press). Nicotine-containing skin patches that are in wide use today can cause local irritation and the absorption of nicotine is slow and affected by cutaneous blood flow. [0018]
  • Also, inhaling devices resembling a cigarette are known for uptake of nicotine vapours as suggested in U.S. Pat. No. 5,167,242. Said means and methods address the problems associated with addiction to nicotine. [0019]
  • Nicotine Chewing Gum [0020]
  • One of the most successful approaches to date in reducing the incidence of smoking relies upon nicotine containing chewing gum that is designed to reduce smoking withdrawal symptoms. The reported success rate is approximately twice that of placebo. The use of the nicotine gum suffers from several problems e.g., that it has been found that the nicotine containing gum does not sufficiently rapidly satisfy the craving that most smokers experience. [0021]
  • Prior Art and Problems Thereof [0022]
  • One successful product that is used as a smoking substitute and/or as a smoking cessation aid and which is based on nicotine, is the chewing gum Nicorette®. This product was one of the first nicotine replacement forms that was approved by the Food and Drug Administration (FDA) and is still one of the most used nicotine replacement products. Nicorette® chewing gum has been on the market in about 60 countries for several years. In this chewing gum the nicotine is present in the form of a complex with an insoluble cation-exchanger (polacrilex) that is dispersed in a gum base. The nicotine is slowly released from the gum due to chewing and will reach similar plasma levels as when smoking a cigarette after about 30 minutes depending on the chewing technique, i.e., slow or active. Patents related to this product are, e.g., the U.S. Pat. Nos. 3,877,468, 3,901,248 and 3,845,217. [0023]
  • WO 98/23165 discloses a chewing gum wherein nicotine may be in the coating. This concept may provide rapid release of the nicotine from the coated chewing gum, but not a sufficiently rapid buccal uptake of the nicotine. The fraction of the released nicotine that is not immediately absorbed will be flushed down in the gastrointestinal (G.I.) tracts by the saliva, thereby possibly causing hiccups and other G.I. side effects. Once absorbed by the G.I. route this swallowed nicotine will be subjected to first pass metabolism. [0024]
  • WO 00/13662 discloses a chewing gum for systemic, oral administration of an active whereby said active is administered by the chewing gum composition in a bi-phasic manner. The bi-phasic delivery is obtained by the gum matrix as such, not from any coating. [0025]
  • WO 00/19977 discloses a substantially moisture free and possibly coated chewing gum for delivery of an active. The possible coating is not said to be buffered. [0026]
  • It is highly desirable in light of the aforementioned problems to develop means and methods for the administration of nicotine to give a satisfaction to a person craving for nicotine or to provide a sense of smoking satisfaction without smoking, which can also avoid problems associated with the prior art means and methods. In this respect, the present invention addresses this need and interest. [0027]
  • SUMMARY
  • In view of the foregoing disadvantages known in the art when trying to deliver nicotine to a subject so as to obtain a rapid transmucosal uptake of nicotine in the oral cavity of the subject the present invention provides a new and improved product, systems and methods for obtaining a rapid transmucosal uptake of nicotine in the oral cavity of the subject. [0028]
  • An object of the present invention is to provide an efficient and effective product, as well as methods and systems for a rapid uptake of nicotine in a subject to avoid the disadvantages of such previously known products and methods. [0029]
  • Thus, the present invention provides a method for delivering nicotine in any form to a subject comprising administering to a subject said coated chewing gum product containing nicotine in any form into the oral cavity of the subject and allowing the nicotine in any form in the coated chewing gum product to be released in the saliva in the oral cavity and absorbed into the systemic circulation of the subject as well as a method for producing said coated chewing gum. [0030]
  • The present invention also provides a method for obtaining reduction of the urge to smoke or use tobacco containing material and/or for providing a sense of smoking satisfaction without smoking, comprising the steps of replacing at least partly the tobacco containing material with above said coated chewing gum product, administering to a subject a coated chewing gum product containing nicotine in any form into the oral cavity of the subject and allowing the nicotine in any form of the coated chewing gum product to be released in the saliva in the oral cavity and absorbed by the subject. [0031]
  • Furthermore, the present invention provides a system for delivering nicotine in any form to a subject, comprising said coated chewing gum product and at least one other means for obtaining reduction of the urge to smoke or use of tobacco as well as a system for obtaining reduction of the urge to smoke or otherwise use of tobacco and/or for providing a sense of smoking satisfaction without smoking, comprising a coated chewing gum product according to above and at least one other method for obtaining reduction of the urge to smoke or otherwise use of tobacco. Said system may be a system wherein the at least other method is selected from the group consisting of administration through mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets and parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods and transmucousal methods; or otherwise use of tobacco. [0032]
  • Still furthermore the present invention relates to a coated chewing gum product comprising at least one chewing gum core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additive, wherein said at least one coating layer is buffered. [0033]
  • Said product may further comprise at least one core being buffered and further may also the nicotine in any form be a part of the at least one coating layer or at least one of the at least one coating layers. The at least one coating is buffered, according to the invention, in such a way that upon administration of the gum the pH of the saliva is increased by 0.3-4 pH units, or preferably increased by 0.5-2 pH units. Said product is buffered by the use of a buffer selected from the group consisting of a carbonate, including bicarbonate or sesquicarbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, such as potassium and sodium, e.g., trisodium and tripotassium citrate, or ammonium, and mixtures thereof. [0034]
  • Use of said product will according to the invention rapidly deliver nicotine in any form to a subject and will also be used for obtaining a quick and/or sustained and/or complete reduction of the urge to smoke or use tobacco and/or for providing a sense of smoking satisfaction without smoking resembling the sense of smoking satisfaction and reduction of the urge to smoke obtained after regular smoking or use of tobacco.[0035]
  • DETAILED DESCRIPTION
  • Definitions [0036]
  • As used herein, the term “chewing gum product” intends to mean all chewable gum products. [0037]
  • The term “fast reduction of the urge to smoke or use tobacco” is herein intended to mean an initial priming of the subject so as to achieve a reduction of the urge to smoke or use tobacco. [0038]
  • The term “sustained” is herein intended to mean prolonged over time. [0039]
  • The term “complete reduction” or “complete” is herein intended to mean complete or substantially complete reduction. [0040]
  • The term “controlled release” is intended to mean a release of a substance from a gum by the aid of active chewing of the gum in the oral cavity of the subject, whereby the active chewing is controlling the amount of substance released. [0041]
  • The term “slow release” is intended to mean that the nicotine is released from the gum upon, e.g., chewing, over a period of time e.g., several minutes to an hour. [0042]
  • The term “unit formula” is intended to mean one chewing gum product. [0043]
  • The term “transient” is intended to mean a non-permanent change, upon which the relevant state, e.g., biological or physiological state, after a certain period of time will return to its value or behaviour prior to said change. [0044]
  • The term “buccal” and “buccally” are herein intended to pertain to all of or any part of the tissue of the oral cavity. [0045]
  • The Coated Chewing Gum [0046]
  • Presently existing nicotine chewing gums provide a slow release and a slow uptake of nicotine. This will not resemble the actual sense of satisfaction when smoking, where an initial fast uptake of nicotine is achieved giving the smoker, i.e., the subject, a sense of satisfaction. Accordingly, as revealed above, the present invention relates to a coated chewing gum product for improving the absorption of nicotine in a subject, and wherein the absorption is quicker than by using current means and methods known in the art of nicotine chewing gums. Such a rapid transmucosal uptake of the nicotine in the oral cavity is expected to give more of a cigarette like sense of satisfaction and a more rapid reduction of the urge to smoke and use tobacco. [0047]
  • According to the invention, a coated chewing gum product is used for improving the absorption of said nicotine. The coated chewing gum product comprises at least one chewing gum core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and at least one other additive, wherein at least one of said coating layer is buffered. [0048]
  • Also, the at least one core may be buffered in different embodiments. The core may be buffered with the same or different ways of buffering as the at least one coating layer. [0049]
  • Said buffering of the at least one coating layer and optionally the at least one core generates a coated chewing gum product giving improved absorption kinetics of nicotine compared to in the art known chewing gum products. [0050]
  • The chewing gum product may be a medicated chewing gum. Medicated chewing gums are herein intended to mean solid or semi-solid, single-dose preparations with a base consisting mainly of gum that are intended to be chewed but not swallowed, where the chewing gums act as a drug delivery system. They contain one or more active substances, which are released by chewing. After dissolution or dispersion of the active substance in the saliva, such chewing gums are used for i) local treatment of mouth diseases and ii) systemic delivery after absorption through transmucosal uptake throughout the oral cavity. [0051]
  • The Buffering Agent [0052]
  • Absorption of nicotine from the oral cavity to the systemic circulation is dependent on the pH of the saliva, pH of the blood plasma and the pKa of nicotine, which is about 7.8. Assuming a pH of the plasma of 7.4 and of the saliva of 6.8 only about 10% of the nicotine will be in the free base form. Thus, in order to promote absorption of nicotine in a free base form, which is the form predominantly absorbed through the mucosa, the pH of the saliva must be increased. At a pH of 8.8 about 90% of the nicotine will then be in the free base form. [0053]
  • Thus according to the invention, the coated chewing gum product is buffered. This may be achieved by including physiologically acceptable buffering substances or agents, or by other means. With other means it is intended to include buffering by any component in the product, which may not normally act as a buffering agent, such as a self-buffering additive or gum base. [0054]
  • According to the invention, at least one coating layer is buffered. In specific embodiments, also the at least one core is buffered. [0055]
  • In specific embodiments, the at least one coating layer is buffered in such a way that upon administration of the gum the pH of the saliva is increased 0.3-4 pH units, preferably 0.5-2 pH units. The buffering is designed so as to achieve a transient buffering of the saliva of a subject during melting, disintegration or dissolution of the coating layer or layers. As the change is transient, the pH will return to its normal value after a certain period of time. [0056]
  • Similarly, the at least one core may be buffered. This may allow said change in the pH to be ensured during chewing of the core of the gum product, where the chewing allows the suitable buffer agent or substance or other means to produce a transient change in the pH of the saliva, e.g., an increase in the pH. [0057]
  • By employing the said change, here as an increase, in said pH of the saliva the transmucosal uptake of nicotine in the oral cavity is changed, e.g., increased compared to the nicotine uptake when the saliva is not buffered according to the invention. Also, since the transmucosal uptake of nicotine in the oral cavity according to the invention is faster than for nicotine not being buffered according to the invention, less nicotine will be swallowed to reach the gastrointestinal (G.I.) tract. The nicotine that reaches the G.I. tract will be subjected to first pass metabolism which reduces the total amount of intact nicotine absorbed. This means that the bio-availability of nicotine that is not co-administered with a buffer according to the invention will generally be lower than when administered together with a buffer. [0058]
  • Further embodiments of the invention includes combinations wherein the at least one coating layer is buffered by the use of a buffer selected from the group consisting of a carbonate including bicarbonate or sesquicarbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, such as potassium or sodium, or ammonium, and mixtures thereof. [0059]
  • Further embodiments may use trisodium or tripotassium citrate, and mixtures thereof. [0060]
  • Still further embodiments may use different phosphate systems, such as trisodium phosphate, disodium hydrogen phosphate; and tripotassium phosphate, dipotassium hydrogen phosphate, and calcium hydroxide, sodium glycinate; and mixtures thereof. [0061]
  • Alkali metal carbonates, glycinates and phosphates are preferred buffering agents. [0062]
  • The one or more buffering agents may to some extent be microencapsulated or otherwise coated as granules with polymers and/or lipids being less soluble in saliva than is the one or more buffering agents. Such microencapsulation controls the dissolution rate whereby is extended the time frame of the buffering effect. [0063]
  • In order to increase the buffering capacity still further without correspondingly increasing the pH, one may in specific embodiments use a second or auxiliary buffering agent to the first buffering agent, such as e.g., sodium or potassium bicarbonate buffers. The second or auxiliary buffering agent may be selected from the group consisting of alkali metal bicarbonates that are preferred for this purpose. Thus, further embodiments of the invention may comprise a mixture of an alkali metal carbonate or phosphate and alkali metal bicarbonate. [0064]
  • The amount of the buffering agent or agents in the chewing gum composition is preferably sufficient in the specific embodiments to raise the pH of the saliva to above 7, as specified above, to transiently maintain the pH of the saliva in the oral cavity above 7, e.g., pH 7-11. [0065]
  • The nicotine may be administered in different forms, e.g., in different complexes or salts. The amount of buffer required to achieve such an increase in pH of the different administered nicotine form is readily calculated by the skilled man in the art. The extent and duration of the increase in pH is dependent on type and amount of the buffering agent(s) used as well as where, i.e., in the at least one coating layer and optionally in the at least one core, the buffer is distributed in the product and is further described within the paragraphs below. [0066]
  • The Coating of the Gum Core [0067]
  • The process of coating a chewing gum is well known in the art. The present invention provides a coating, to facilitate the uptake of administered nicotine in any form to the subject. Known intentions of coating a chewing gum product may be to add crispiness, enhance taste, or to protect the gum, e.g., during storage, or as to tone down bad or irritating taste of the gum product. [0068]
  • According to the invention, the chewing gum is a coated chewing gum comprising at least one coating layer. [0069]
  • The different embodiments according to the invention may use sugar coating, film coating, press/compression coating or melt coating. [0070]
  • For the film and sugar coating, the coating procedure may be manual or the coating may be sprayed onto the gum core/pellet in rotating pans of different shapes or fluidised beds in combination with evaporation of the solvent, e.g., water or organic solvent. [0071]
  • Sugar coating is a multistep process and may be divided into the following steps: 1. sealing of the cores; 2. subcoating; 3. smoothing, or glossing; 4. colouring; 5. polishing; and 6. optionally printing [0072]
  • Sugar coated cores have a smoother profile with less visible edges remaining from the original core. Sub-coating, e.g., either by dusting with powder on the sucrose solution or application of dry powder in the sucrose solution, may be used. The core may be sugar coated by a panning technique, e.g., using a sugar coating pan, or other more sophisticated techniques capable of some degree of automation. [0073]
  • The sugar in a sugar coating may not be just sucrose. Also other types of sugar may do as well, e.g., sugar alcohols (polyalcohol, polyol). [0074]
  • The sugar used in the sugar coating may according to specific embodiments also be an artificial sweetener, being low or substantially free of calories and less caries promoting than regular sugar, or a combination with sugar and/or sugar alcohol. [0075]
  • Film coating involves the deposition, usually by a spray method, of a thin film of polymer surrounding the core. The solution may be sprayed on to a rotated, mixed bed. The drying conditions permit the removal of the solvent so as to leave a thin deposition of coating material around each core. [0076]
  • The composition of the coating solutions and suspensions may differ during different parts of the process. [0077]
  • Press coating involves the compaction of granular material around an already manufactured core. Using press/compression coating, a further core is pressed on the outside of the initial core/cores. [0078]
  • Example 1-4 describes four different coatings and coating compositions that may be used according to the invention, i.e., sugar coating in example 1, film coating in example 2, press coating in example 3 and melt coating in example 4, all onto a chewing gum core. The coating is buffered in each case and contains nicotine as well. The coatings in example 1-4 may be combined with different cores. Examples of cores are given in Example 5 and further described below. [0079]
  • If nicotine hydrogen tartrate (NHT) is used as the nicotine form then NHT and buffer are suitably separated from each other in the coating by keeping them in separate layers, especially when sugar coating is used. A moisture barrier between the NHT-containing layer and the coating comprising the buffer may be applied to prevent interaction between the acid salt NHT and the buffer during the coating process. Suitable moisture barriers are e.g. ethylcellulose or a combination of ethylcellulose and hydroxypropyl methylcellulose (HPMC) and/or plasticizer from an organic solvent or solvent mixture, aqueous ethylcellulose dispersion such as Aquacoat EDC (FMC Corp.) or Surelease (Colorcon) preferably in combination with plasticizer, Sepifilm LP 007 or LP 010 (Seppic)—based mainly on HPMC and stearic acid—, Opadry AMB or High Performance Opadry II (Colorcon)—based mainly on polyvinylalcohol—, and polymethacrylates as Eudragit L30 D-55 or EPO (Röhm). Depending on the type of barrier film selected the moisture barrier preferably accounts for a weight of around 0.3% to around 5% of the total weight of the coating. [0080]
  • An additive may be added to the coating or the core/s. Additives are further described in the paragraph entitled “Other additives to the chewing gum”. [0081]
  • The Core [0082]
  • The amount of gum base in the coated chewing gum according to the invention is about 15-80% by weight of the total gum core, and preferably at least about 40%. The amount of gum base employed for the most desirable slow release of nicotine is usually in the higher ranges when nicotine is employed per se or when an absorbed form is used. [0083]
  • The gum base may be of any conventional nature known in the art. For example it may comprise a gum base of natural or synthetic origin readily available from a commercial source. Natural gum bases include, e.g., chicle, jelutong-, lechi de caspi-, soh-, siak-, katiau-, sorwa-, balata-, pendare-, malaya-, and peach gums, natural cautchouc and natural resins such as dammar and mastix. Synthetic gum bases are a mixture of: [0084]
  • elastomers (polymers, masticating substances), [0085]
  • plasticizer (resin, elastomers, solvent, hydrophobic resin), [0086]
  • filler (texturizer, water-insoluble adjuvant), [0087]
  • softener (fat), [0088]
  • emulsifier, [0089]
  • wax, [0090]
  • antioxidant, [0091]
  • and anti-tacking agents (vinyl polymer, hydrophilic resin). [0092]
  • Other examples of gum bases are gums including agar, alginate, arabic gum, carob gum, carrageenan, ghatti gum, guar gum, karaya gum, pectin, tragacanth gum, locust beam gum, gellan gum and xanthan gum. [0093]
  • Examples of gelling agents comprise gum arabic, starch, gelatine, agar, and pectin. [0094]
  • When the nicotine in any form and the buffering agent or agents are incorporated in the chewing gum mass in accordance with the present invention, it is possible to employ a wide variety of chewing gum compositions and amounts of the chewing gum base. Different chewing gum products may be composed depending on the consumers preference and the purpose of use, in respect of the nicotine level, nicotine distribution and other additives. [0095]
  • The Active Ingredient [0096]
  • According to the invention, the chewing gum product comprises nicotine in any form and/or a nicotine mimicking agent. In specific embodiments, the nicotine is part of the at least one coating layer or at least one of the at least one coating layers. [0097]
  • In still further embodiments, the nicotine is a part of the chewing gum core or at least one of the chewing gum cores. [0098]
  • In still even further embodiments, the nicotine is part of the at least one coating layer or at least one of the at least one coating layers and the chewing gum core or at least one of the chewing gum cores to give a fast transmucosal uptake of the nicotine in the oral cavity of a subject so as to obtain a rapid kick or reduction of the urge to smoke and/or use tobacco. Thereby may also be achieved a systemic maintenance level of nicotine. [0099]
  • The nicotine should be in a saliva soluble form to facilitate the release of the agent into the saliva in the oral cavity and, further, the subsequent uptake of the nicotine from the saliva in the oral cavity into the systemic circulation of the subject. [0100]
  • In preferred embodiments, the nicotine in any form is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine inclusion complex or nicotine in any non-covalent binding; nicotine bound to zeolites; nicotine bound to cellulose or starch microspheres; and mixtures thereof. Still, further the inclusion complex may be a cyclodextrin, such as β-cyclodextrin. Even further the cation exchanger may be a polyacrylate. Even more further, the nicotine salt may be a tartrate, hydrogen tartrate, citrate or malate. [0101]
  • According to the invention, the uptake of the nicotine through any tissue or mucosa in the oral cavity, i.e., the absorption kinetics, is improved in relation to the uptake obtained by known chewing gum products for nicotine uptake. [0102]
  • The nicotine may act as a stimulant to e.g., obtain a rapid reduction of the urge to smoke or to use tobacco. [0103]
  • With nicotine it is intended to include nicotine, 3-(1-methyl-2-pyrrolidinyl)-pyridine, with its base form, including synthetic nicotine as well as nicotine extracts from tobacco plants, or parts thereof, such as the genus Nicotiana alone or in combination; or pharmaceutically acceptable salts. [0104]
  • The most preferable embodiment incorporates nicotine as the free base form or as a water-soluble pharmaceutically acceptable salt, either per se or adsorbed on a adsorbent, or as a complex with a cation exchanger or mixtures of the foregoing, as an inclusion complex, such as a cyclodextrin complex, e.g., β-cyclodextrin, but any other suitable pharmaceutically acceptable form may also be employed. [0105]
  • Numerous nicotine salts are known, and may be used, e.g., the salts presented in Table 1, such as preferably the tartrate, hydrogen tartrate, citrate, malate, and/or hydrochloride. [0106]
    TABLE 1
    Possible acids used for nicotine salt formation
    Molar ratio* of
    Acid acid:nicotine
    Formic 2:1
    Acetic 3:1
    Propionic 3:1
    Butyric 3:1
    2-Methylbutyric 3:1
    3-Methylbutyric 3:1
    Valeric 3:1
    Lauric 3:1
    Palmitic 3:1
    Tartaric 2:1
    Citric 2:1
    Malic 2:1
    Oxalic 2:1
    Benzoic 1:1
    Gentisic 1:1
    Gallic 1:1
    Phenylacetic 3:1
    Salicylic 1:1
    Phthalic 1:1
    Picric 2:1
    Sulfosalicylic 1:1
    Tannic 1:5
    Pectic 1:3
    Alginic 1:2
    Hydrochloric 2:1
    Chloroplatinic 1:1
    Silicotungstic 1:1
    Pyruvic 2:1
    Glutamic 1:1
    Aspartic 1:1
  • The product according to the invention may also comprise a nicotine mimicking agent. Such an agent may be any suitable agent with an acrid burning taste. Examples of nicotine mimicking agents with an acrid burning taste are capsaicin, piperine and zingerone. [0107]
  • One or more additives may be added to the coating or the core/s. Additives are further described in the paragraph entitled “Other additives to the chewing gum”. [0108]
  • Amount and Distribution of the Nicotine in the Coated Chewing Gum [0109]
  • The nicotine in any form is according to the invention formulated to provide the subject with a dose to achieve an effect. The effect may be to provide a sense of smoking satisfaction without smoking. Another effect of the administered nicotine in any form may be a reduction of the urge to smoke or use tobacco. [0110]
  • The effect may also be a combination of reduction of said urge and providing a sense of smoking satisfaction without smoking. The amount of the nicotine should be sufficient to provide such an effect in a subject. This amount may, of course, vary from person to person. [0111]
  • According to the invention, embodiments of the chewable gum product comprise embodiments wherein nicotine in any form is present in an amount of 0.05-10 mg calculated as the free base form of nicotine per piece coated chewing gum product. This may in different embodiments include 0.05, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg calculated as the free base form of nicotine per piece coated chewing gum product. [0112]
  • Still preferred embodiments may contain embodiments where the nicotine in any form is present in an amount of 0.5-6 mg calculated as the free base form of nicotine per piece coated chewing gum product. [0113]
  • Even more preferred embodiments contain the nicotine in any form in an amount of 0.5-4 mg calculated as the free base form of nicotine per piece coated chewing gum product. [0114]
  • According to certain embodiments of the invention, the nicotine in any form is part of the at least one coating layer or at least one of the at least one coating layer. [0115]
  • The nicotine in any form may be in an amount of 0-10 mg calculated as free base form in at least one of the at least one coating layer. Still further embodiments comprise nicotine in an amount of 0.2-6 mg in at least one of the at least one coating layers, or even more preferably, in an amount of 0.5-5 mg in at least one of the at least one coating layer. [0116]
  • The nicotine in any form may be distributed in the core and/or different coating layers in different embodiments. Different distributions of the nicotine throughout the coated chewing gum will imply administration of the nicotine to the subject in different ways. This may, then, provide several possibilities to adjust the composition of the coated chewing gum according to different needs of different subjects depending on the urge to smoke or use tobacco of the subject. [0117]
  • Release and Uptake of Nicotine [0118]
  • Presently existing nicotine chewing gums provide a slow release and a slow uptake of the nicotine compared to smoking. The slow uptake of the nicotine provides a t[0119] max, i.e., the time-point where the nicotine has its maximum level measured in the plasma of venous blood, after a single dose at about 30 minutes after administration. The tmax is initially preceded by a lag period of a couple of minutes where no nicotine can be detected in the blood. Then, the plasma level is gradually increasing till the tmax is reached.
  • The time point for reaching a sense of satisfaction or reduction of urge to smoke or use tobacco after the initial lag period is individual, but may in existing chewing gums generally be reached after approximately 30 minutes when regarded as coinciding with t[0120] max. According to the present invention, such a sense of satisfaction may be reached after a shorter period of time due to a rapid initial burst dose of nicotine in the coating followed by a rapid transmucosal uptake in the oral cavity due to the buffered coating.
  • The release of the nicotine in the coated chewing gum according to the invention proceeds in at least one step. [0121]
  • I) If the nicotine is, as in preferred embodiments, in a defined amount, such as the amounts described above according to different embodiments, in at least one of the at least one coating layers defined above the release of the nicotine takes place when the coating of the coated chewing gum is allowed to melt, disintegrate or dissolve to uncover the chewable gum core in said product. The nicotine and forms thereof is released from the coating into the saliva in the oral cavity during the time period when the coating is allowed to melt, disintegrate or dissolve. [0122]
  • When the at least one coating layer is allowed to melt, disintegrate or dissolute a chewable gum is uncovered. The nicotine in any form may then further be released to the subject. [0123]
  • II) The nicotine in any form from the chewable gum is released by controlled release, e.g., by chewing the gum core whereby the chewing is controlling the amount of released nicotine from the gum core. The release of the nicotine is thereby sustained over a period of time. This period of time may be, in different embodiments about 10, 20, 30, 40, 50, or 60 minutes. [0124]
  • The dissolution of the one or more buffering agents in the coating, and optionally in the core(s), provides for optimized adjustment of the pH of the liquid in the oral cavity. [0125]
  • The release may be varied by the incorporation of the nicotine in any form in a given quantity into the coating layers and/or the gum core. [0126]
  • Suitable cat ion exchangers are given in table 2 and are further disclosed in U.S. Pat. No. 3,845,217, hereby included as a reference. Preferred are nicotine cation exchangers of polyacrylates, such as the Amberlite collection from Rohm & Haas in table 2. Examples of different salts are given in Table 1. [0127]
    TABLE 2
    Representative cation exchangers
    Name Manufacturer
    Amberlite IRC 50 Rohm & Haas
    Amberlite IRP 64 Rohm & Haas
    Amberlite IRP 64M Rohm & Haas
    BIO-REX 70 BIO-RAD Lab.
    Amberlite IR 118 Rohm & Haas
    Amberlite IRP 69 Rohm & Haas
    Amberlite IRP 69M Rohm & Haas
    BIO-REX 40 BIO-RAD Lab.
    Amberlite IR 120 Rohm & Haas
    Dowex 50 Dow Chemical
    Dowex 50W Dow Chemical
    Duolite C 25 Chemical Process Co
    Lewatit S 100 Farbenfabriken Bayer
    Ionac C 240 Ionac Chem.
    Wofatit KP S 200 I.G. Farben Wolfen
    Amberlyst 15 Rohm & Haas
    Duolite C-3 Chemical Process
    Duolite C-10 Chemical Process
    Lewatit KS Farbenfabriken Bayer.
    Zerolit 215 The Permutit Co.
    Duolite ES-62 Chemical Process
    BIO-REX 63 BIO-RAD Lab.
    Duolite ES-63 Chemical Process
    Duolite ES-65 Chemical Process
    Ohelex 100 BIO-RAD Lab.
    Dow Chelating Resin A-1 Dow Chemical Company
    Purolite C115HMR Purolite International Ltd.
    CM Sephadex C-25 Pharmacia Fine Chemicals
    SE Sephadex C-25 Pharmacia Fine Chemicals
  • Not only the amount of the nicotine released from the different parts of the chewing gum product is of value as known in the art, but also, according to the present invention the specific transmucosal uptake from the oral cavity of the nicotine to the systemic circulation of the subject whereby the one or more buffering agents account for provision of a suitable adjustment of the pH of the liquid of the oral cavity. The uptake according to the invention is further discussed in the method paragraphs below. [0128]
  • Other Additives to the Chewing Gum [0129]
  • Other additives may be added optionally to the chewing gum core and/or to coating layers in the chewing gum. [0130]
  • Optional additives comprise at least one or more additive selected from the group consisting of stabilisers, such as preservatives, e.g., antioxidants; softeners, thickening agents, emulsifiers, glidants, lubricants, sweeteners, flavours, aromatics, enhancers, colouring agents, vitamins, minerals, fluorine and tooth whitening agents and mixtures thereof. According to the invention, at least one of such additives is optionally added to the product. [0131]
  • Enhancers are added essentially to improve, i.e., increase, the transmucosal uptake from the oral cavity. [0132]
  • Sweeteners are added essentially to improve the taste. [0133]
  • Sweeteners comprise one or more synthetic or natural sugars, i.e., any form of carbohydrates suitable for use as sweetener, as well as so called artificial sweeteners such as saccarin, sodium saccarin, aspartame, e.g., NutraSweet®, acesulfame K or acesulfame, potassium acesulfame, thaumatin, glycyrrhizin, sucralose, dihydrochalcone, alitame, miraculin, monellin, stevside. [0134]
  • Suitable sweeteners may be selected from the group consisting of sugar alcohols, such as sorbitol, xylitol, single sugars including sugars extracted from sugar cane and sugar beet (sucrose), dextrose (also called glucose), fructose (also called leavulose), and lactose (also called milk sugar); sorbitol, mannitol, glycerol, xylitol, maltitol syrup (or hydrogenated starch hydrolyzate), isomalt, lactitol; and mixtures of sugars including glucose syrup, e.g., starch hydrolysates, containing a mixture of dextrose, maltose and a range of complex sugars, invert sugar syrup, e.g., sucrose inverted by invertase (also called sucrase or sacchrase) containing a mixture of dextrose and fructose, high sugar content syrups such as treacle and honey containing a mixture of particular leavulose, dextrose, maltose, lactitole, sucrose, resins, dextrin and higher sugars; and malt or malt extracts. [0135]
  • The flavour and aroma additives may comprise one or more synthetic or natural flavouring or aromatizing agents. [0136]
  • Flavour and aroma agents may be selected from essential oils including distillations, solvent extractions, or cold expressions of chopped flowers, leaves, peel or pulped whole fruit comprising mixtures of alcohols, esters, aldehydes and lactones; essences including either diluted solutions of essential oils, or mixtures of synthetic chemicals blended to match the natural flavour of the fruit, e.g., strawberry, raspberry and black currant; artificial and natural flavours of brews and liquors, e.g., cognac, whisky, rum, gin, sherry, port, and wine; tobacco, coffee, tea, cocoa, and mint; fruit juices including expelled juice from washed, scrubbed fruits such as lemon, orange, and lime; spear mint, pepper mint, wintergreen, cinnamon, cacoe/cocoa, vanilla, liquorice, menthol, eucalyptus, aniseeds nuts (e.g., peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts), almonds, raisins; and powder, flour, or vegetable material parts including tobacco plant parts, e.g., genus Nicotiana, in amounts not contributing significantly to the level of nicotine, and ginger. [0137]
  • Colouring additives may be selected from dyes being approved as a food additive. [0138]
  • Stabilizing additives may be selected from the group consisting of antioxidants including vitamin E, i.e., tocopherole, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid and edetate salts; and preservatives including citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid. Preferred embodiments comprise an antioxidant as the stabiliser, and even more preferably the antioxidant vitamin E and/or butylated hydroxytoluene (BHT). [0139]
  • Method for Delivering Nicotine in any Form to a Subject [0140]
  • According to the invention, a method for delivering nicotine in any form to a subject comprises the steps of [0141]
  • a) administering to a subject a coated chewing gum product containing nicotine in any form according to the invention into the oral cavity of the subject, and [0142]
  • b) allowing the nicotine in any form in the coated chewing gum product to be released in the saliva in the oral cavity and absorbed into the blood plasma of the subject. [0143]
  • According to the invention, the transmucosal uptake of the nicotine in the oral cavity is more rapid than with presently known chewing gum not being buffered in the coating. One embodiment results in a t[0144] max of nicotine in venous blood of the subject after about 5-20 minutes.
  • In still one embodiment, said nicotine in any form is absorbed resulting in a t[0145] max of nicotine in venous blood of the subject after about 3-15 minutes.
  • The method for delivering nicotine in any form may further comprise the steps of [0146]
  • c) administering the nicotine in any form in a sustained way over a period of time to the subject. [0147]
  • Such a time period may be at least 10, 20, 30, 40, 50 or 60 minutes. [0148]
  • Method for Obtaining Reduction of the Urge to Smoke or Use of Tobacco [0149]
  • A method for obtaining reduction of the urge to smoke or use tobacco containing material and/or for providing a sense of smoking satisfaction without smoking according to the invention comprises the steps of [0150]
  • a) replacing at least partly the tobacco containing material with a coated chewing gum according to any of claims [0151] 1-20,
  • b) administering to a subject a coated chewing gum product containing nicotine in any form according to any of claims [0152] 1-20 into the oral cavity of the subject, and
  • c) allowing the nicotine in any form in the coating of the coated chewing gum product to be released in the saliva in the oral cavity and absorbed by the subject. [0153]
  • In one embodiment said nicotine in any form results in a t[0154] max of nicotine in venous blood of the subject after about 5-20 minutes.
  • In a further embodiment, the absorbing of said nicotine released from the at least one coating layer is resulting in a t[0155] max of nicotine in venous blood of the subject after about 3-15 minutes.
  • In still another embodiment, the method according to the invention further comprises the steps of administering the nicotine in any form in a sustained way over a period of time to the subject. [0156]
  • The period of time may be at least 10, 20, 30, 40, 50 or 60 minutes. [0157]
  • Even further embodiments of the method for delivering nicotine to a subject may comprise the steps of combining at least one other method for obtaining reduction of the urge to smoke or use of tobacco. [0158]
  • Tobacco containing material may be material used for e.g., smoking, snuffing or chewing and may comprise a cigarette, a cigarr, snuff, pipe tobacco and also chewing tobacco. [0159]
  • The coated chewing gum product may be used for obtaining a quick and/or sustained and/or complete reduction of the urge to smoke or use of tobacco and/or for providing a sense of smoking satisfaction without smoking as further discussed below. [0160]
  • The fast relief provides the subject with a sense of rapid smoking satisfaction without smoking. Such a satisfaction will decrease the craving more rapidly than other known nicotine chewing gum products. [0161]
  • The quick craving relief is obtained when a dosage of nicotine is released from at least one of the at least one coating layers of the coated chewing gum in embodiments wherein nicotine is in the coating layers in the presence of one or more buffering agents in the coating and optionally in the core(s). This provides the subject with an initial rapid transmucosal uptake of nicotine in the oral cavity that will induce an initial peak, a maximum, in the blood plasma nicotine levels after a certain time, t[0162] max. The result will be that the subject gets a feeling or sense of satisfaction and the initial craving will disappear.
  • One embodiment reduces the urge to smoke or use of tobacco by reaching a t[0163] max of nicotine in venous blood of the subject after about 5-20 minutes by the use of a coated chewing gum according to the invention.
  • Still one embodiment reduces the urge to smoke or use of tobacco quickly resulting in a t[0164] max of nicotine in venous blood of the subject after about 3-15 minutes when said nicotine in any form is released from the at least one coating layer after use of a coated chewing gum according to the invention.
  • Sustained Reduction of the Urge to Smoke or Use of Tobacco [0165]
  • Still, to continue the feeling or sense of satisfaction of the subject, and to avoid that the craving returns, a sustained craving relief may be obtained after the initial craving relief. A sustained craving relief is obtained by chewing the gum part, or core, of the coated chewing gum to allow a sustained uptake of the nicotine. The sustained craving relief and/or feeling or sense of satisfaction of the subject will continue as long as the subject maintains the blood plasma levels of nicotine at a level high enough to reach this sense of feeling. [0166]
  • The subject may achieve this by chewing the gum part of the chewing gum over a period of time, such as 10, 20, 30, 40, 50, or even 60 minutes or longer, e.g., a slow release of the nicotine caused by a controlled release, e.g., by individual chewing. [0167]
  • Cessation of the Urge to Smoke or Use of Tobacco [0168]
  • For some of the users, it may be a goal to terminate the usage of nicotine completely, due to several reasons e.g., health, economical, social or behavioural. This may be achieved by further decreasing the amount of nicotine in any form gradually over time. In a specific embodiment of the invention, the method described above for obtaining craving relief may further comprise the steps of decreasing the amount of nicotine in the total coated chewing gum product described above gradually over time, so as to achieve a complete relief of tobacco craving. This method results in a weaning process gradually over time. [0169]
  • Different types of smokers reach the sense of reduced craving at different plasma levels of nicotine. This may, of course, affect the individual types of administration programs of a coated chewing gum according to the invention. Different types of smokers include e.g., peak seekers or smokers that crave for a plasma level of nicotine constantly being above the level for withdrawal symptoms. [0170]
  • One strategy may be to lower the frequency of the administered coated chewing gums. Other embodiments include varying the dose of the nicotine in said gums as well as the combination of these two. Also, the strategy may include a coated chewing gum with substantially no nicotine in any form. Such a gum may be administered at the end of the treatment period, when the craving is low or substantially absent. [0171]
  • Systems for Delivering Nicotine and for Obtaining Craving Relief [0172]
  • According to the invention there is a system for delivering nicotine in any form to a subject. Such a system comprises a coated chewing gum according to the invention and at least one other means for obtaining reduction of the urge to smoke. [0173]
  • Another system according to the invention may also be a system for obtaining reduction of the urge to smoke or use of tobacco and/or for providing a sense of smoking satisfaction without smoking. Such a system comprises a coated chewing gum product according to the invention and at least one other method for obtaining reduction of the urge to smoke or use tobacco. Other methods may also be a concomitant or concurrent method selected from the group consisting of administration through mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets and parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods and transmucosal methods; or use of tobacco. [0174]
  • In a specific embodiment, the at least other method comprises administration of nicotine. [0175]
  • Use of the Coated Chewing Gum [0176]
  • The use of the coated chewing gum product according to the invention is for obtaining a fast and/or sustained and/or complete reduction of the urge to smoke and use tobacco or for providing a sense of smoking without smoking as described above. [0177]
  • The dose of the nicotine is chosen to give the subject an individual sensory perception and satisfaction with an effect of the nicotine in any form. The use of the coated chewing gum product may also be a sole use according to the invention or a combination with other means or methods known in the field of drug abuse. Specifically, the present invention may be used in combination with other means as described above in the methods in the paragraphs above. [0178]
  • The use may give a quick reduction of the urge to smoke or use tobacco obtained reaching a t[0179] max of nicotine in venous blood after e.g., about 5-20 minutes.
  • In a specific embodiment, the use of the coated chewing gum according to the invention will reduce the urge to smoke or use tobacco by reaching a t[0180] max, of nicotine in venous blood of the subject after about 3-15 minutes when said nicotine in any form is released from the at least one coating layer.
  • According to the invention, a use of a coated chewing gum product according to the invention is also disclosed for delivering nicotine in any form to a subject. [0181]
  • In one embodiment, the delivering of nicotine in any form results in a t[0182] max of nicotine in venous blood of the subject after about 5-20 minutes.
  • In still another embodiment, the delivering of nicotine in any form results in a t[0183] max of nicotine in venous blood of the subject after about 3-15 minutes when said nicotine in any form released from the at least one coating layer is absorbed.
  • Production of the Coated Chewing Gum [0184]
  • Coated chewing gum products according to the invention can be maintained in several production steps depending on the total number of cores and the total number of coated layers to be included. [0185]
  • A method for the production of the coated chewing gum according to the invention is disclosed. [0186]
  • The method comprises the steps of [0187]
  • a) providing at least one chewing gum core, and/or providing at least one nicotine containing chewing gum core, [0188]
  • b) providing nicotine in any form, [0189]
  • c) providing at least one coating layer that is buffered, [0190]
  • d) adding the nicotine in any form to the at least one chewing gum core and/or to the at least one coating, and [0191]
  • e) coating the at least one chewing gum core with the at least one coating layer that is buffered. [0192]
  • The method may in specific embodiments further comprise [0193]
  • f) buffering the at least one chewing gum core, and/or [0194]
  • g) providing at least one coating layer not being buffered, and optionally [0195]
  • h) adding the nicotine in any form to at least one of said at least one coating layer not being buffered, and optionally [0196]
  • i) providing the nicotine in the coating and the buffer in the coating in separate layers, preferably separated by a moisture barrier. [0197]
  • In one embodiment, the nicotine is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine inclusion complex or nicotine in any non-covalent binding; nicotine bound to zeolites; nicotine bound to cellulose or starch microspheres; and mixtures thereof. [0198]
  • The at least one coating layer may in some embodiments be buffered by the use a buffer selected from the group consisting of a carbonate buffer, such as the carbonate, bicarbonate, sesquicarbonate of an alkali metal, e.g., potassium, sodium; or ammonium; sodium glycinate, alkali metal phosphate, sodium or potassium glycerophosphate, trisodium or tripotassium citrate, and mixtures thereof wherein the at least one coating layer is buffered in such a way that upon administration of the gum the pH of the saliva is increased by 0.3-4 pH units. The buffering may be transient. [0199]
  • In still further embodiments, the at least one coating layer is buffered in such way that upon administration of the gum the pH of the saliva is increased by 0.5-2 pH units. The core/pellet composition may be formed simply by mixing, rolling and scoring or compression of the chewing gum base with at least one of the forms of nicotine, e.g., the nicotine-ion exchanger complex, or the nicotine as a free base or a salt. Before adding any solid component, except for the gum base, it is desirable to grind and size the solid component first, to ensure good distribution. The mixing is preferably conducted at a suitably elevated temperature depending on the viscosity of the gum core used. The increase in temperature decreases the viscosity of the gum and thereby enables the nicotine and other additives to be evenly and intimately distributed within the core/pellet of the chewing gum. [0200]
  • Example 5 describes the mixing, rolling and scoring as well as the compression of gum cores. In principle, this procedure may be applied for coated chewing gum products up to at least 10 mg unit formula. [0201]
  • Mixing, rolling and scoring is done by a conventional procedure. Double sigma blade mixers are used for mixing the gum base with the other components of the formulation. The gum base is softened in the mixer. By heat (from the heating jacket) and mixing, the gum base becomes plastic. So, the softened base is mixed with the liquid components, e.g., flavours, liquid, sorbitol and glycerol, nicotine in base form, when used, and the solid materials, e.g., nicotine in any form other than in liquid form, buffer, bulk sweetener, colour as a powder mixture. The warm mass is discharged from the mixer in form of loaves stacked on trays on a truck and stored in a conditioned area until the next step starts. This is to cool the gum. [0202]
  • After this, the rolling and scoring takes place. The gum is extruded into a thick sheet, which is rolled by multiple sets of calender rolls to the correct thickness. The scoring rolls, usually two sets, cut the gum into the correct size. [0203]
  • The sheets are then transferred to a conditioned area on trays, where the sheets are cooled to make them brittle enough to be broken. The conditioned gum sheets are then passed through a breaker, which is a rotating drum that parts the sheets into separate pieces of gum along the scores. [0204]
  • At a sorting stage deformed gums are sorted away. The accepted gums are passed through a metal detector. [0205]
  • Chewing gums produced by compression, i.e., tabletted gums are made out of a special gum base. Such a gum base gives a rapid hydration of the cud in the mouth. High velocity mixers can be used for granulation to give correctly sized particles of the mixture. This mixture is then compressed in a tablet machine. [0206]
  • At a sorting stage deformed gums are sorted away. The accepted gums are passed through a metal detector. [0207]
  • In one embodiment of the method disclosed, the provision of the at least one chewing gum core in step a) above comprises the further steps of [0208]
  • a1) providing a gum core dough, [0209]
  • a2) mixing, rolling and scoring; molding; or extruding the gum dough. [0210]
  • In still another embodiment, the provision of the chewing gum core in step a) is obtained by direct compressing of the ingredients. [0211]
  • Conveniently, the compositions of additives according to the invention, e.g., the buffer system, are made simultaneously, according to known procedures in the art for formulating the buffers. Depending on the physical properties of the buffer system incorporated, it may be convenient to add the buffer system/s either with the liquid part or with he solid part of the composition. In the case of buffering systems available as fine powders, it may, of course, be most convenient to add those powders with the solid, powdered part of other additives. [0212]
  • The gum mass with additives is cooled, rolled, scored and hardened sufficiently, and then coated according to the paragraph The coating of the gum core/pellet. [0213]
  • According to the method disclosed in the invention, some embodiments are disclosed where the coating of the at least one chewing gum core with at least one layer of the at least one buffered coating comprises the steps of [0214]
  • a) film coating, and/or [0215]
  • b) press coating, and/or [0216]
  • c) sugar coating, and/or [0217]
  • d) melt coating. [0218]
  • The product may then be analysed and further wrapped. [0219]
  • Use for Therapy and Treatment [0220]
  • The coated chewing gum product according to the invention may be used in therapy. Said therapy may be a treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control. [0221]
  • The nicotine may also be used for the production of a chewing gum product according to the invention for the treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control. [0222]
  • Also disclosed is the use of a chewing gum product for the production of a nicotine containing chewing gum product according to the invention for the treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, and ulcerous colitis. [0223]
  • Analysis of Nicotine [0224]
  • The analysis of nicotine uptake and effect according to the invention may be done according to standard procedure known in the art, e.g., using a bioanalys for the determination of nicotine or its metabolites in the plasma of a subject. [0225]
  • EXAMPLES
  • The below examples are illustrative and non-limiting. [0226]
  • Example 1 Buffered Sugar Coating
  • This example describes without limiting the invention a sugar coating, wherein the coating is buffered and wherein the nicotine is in the coating. [0227]
  • Objective [0228]
  • The objective of this example is to provide a sugar coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. The nicotine is in the amount of 1, 2, 4 or 5 mg, respectively. [0229]
  • Material Sugar Coating* [0230]
  • A. Nicotine Free Base [0231]
    1 mg 2 mg 4 mg 5 mg unit
    unit formula unit formula unit formula formula
    Component (mg) (mg) (mg) (mg)
    Sorbitol 19.0 22.2 28.7 31.9
    Mannitol 29.4 29.4 29.4 29.4
    Xylitol 162 162 162 162
    Water q.s.** q.s. q.s. q.s.
    Gelatin 3.4 3.4 3.4 3.4
    Titanium dioxide 2.5 2.5 2.5 2.5
    Sodium carbonate 10 15 20 20
    Nicotine free base 1 2 4 5
  • B. Nicotine Hydrogen Tartrate [0232]
    1 mg 5 mg
    unit formula unit formula
    Component (mg) (mg)
    Sorbitol 19.0 31.9
    Mannitol 29.4 29.4
    Xylitol 162 162
    Water q.s. q.s.
    Gelatin 3.4 3.4
    Sodium carbonate 15 40
    Titanium dioxide 2.5 2.5
    Nicotine hydrogen tartrate, N.H.T. 3.1 15.4
    (corresponding to nicotine free base) 1 5
  • Results and discussion [0233]
  • Other amounts of nicotine are possible. [0234]
  • Example 2 Buffered Film Coating
  • This example describes without limiting the invention a film coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. [0235]
  • Objective [0236]
  • The objective of this example is to provide a film coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. The nicotine is in the amount of 1, 2, 4 or 5 mg, respectively. [0237]
  • Material Film Coating [0238]
  • A. NHT [0239]
    1 mg unit 4 mg tablet unit
    formula 2 mg unit formula formula
    Component (mg) (mg) (mg)
    HPMCa, 5cPs 15.9 15.9 15.9 20 20
    PEGb 4000/6000 4.8 0 4.8 0 4.8
    Water 27 27 27 34 34
    Ethanol 221 221 221 278 278
    NHT, 3.1 (1) 6.2 (2) 6.2 (2) 12.3 (4) 12.3 (4)
    (corresponding to
    nicotine free base,
    mg)
    Paraffin wax 0.7 0.7 0.7 0.7 0.7
    Sodium carbonate 15 20 20 35 35
  • B. Nicotine Free Base [0240]
    1 mg 2 mg 4 mg 5 mg unit
    unit formula unit formula unit formula formula
    Component (mg) (mg) (mg) (mg)
    HPMCa, 5cPs 19.0 19.0 19.0 19.0
    PEGb 4000/6000 4.8 4.8 4.8 4.8
    Water 27 27 27 27
    Ethanol 221 221 221 221
    Paraffin wax 0.7 0.7 0.7 0.7
    Sodium carbonate 15 15 20 20
    Nicotine free base 1 2 4 5
  • Example 3 Buffered Press Coating
  • This example describes without limiting the invention a press coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. [0241]
  • Objective [0242]
  • The objective of this example is to provide a press coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. The nicotine is in the amount of 1, 2, 4 or 5 mg, respectively. [0243]
  • Material Press Coating [0244]
  • A. NHT [0245]
    1 mg unit 2 mg unit 4 mg unit 5 mg unit
    Component formula formula formula formula
    Xylitab 100 734 731 725 722
    HPMC, 3cPs 238 238 238 238
    Sodium carbonate 10 20 30 40
    Magnesium stearate 10 10 10 10
    Nicotine hydrogen 3.1 6.2 12.3 15.4
    tartrate,
    corresponding to 1 2 4 4
    nicotine free base
  • B. NRC or NCC [0246]
    2 mg unit 4 mg unit
    formula (mg) formula (mg)
    Component NRC NCC NRC NCC
    Xylitab 100a 727 720 717 703
    HPMC, 3cPs 238 238 238 238
    Sodium carbonate 15 15 30 30
    Magnesium stearate 10 10 10 10
    NRC 10 20
    (corresponding to 2 4
    nicotine free base)
    NCC 17.1 34.2
    (corresponding to 2 4
    nicotine free base)
  • Example 4 Buffered Melt Coating
  • This example describes without limiting the invention a melt coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. [0247]
  • Objective [0248]
  • The objective of this example is to provide a melt coated chewing gum, wherein the coating is buffered and wherein the nicotine is in the coating. The nicotine is in the amount of 1, 2, 4 or 5 mg, respectively. [0249]
  • Material Melt Coating [0250]
  • A. NHT [0251]
    1 mg unit 2 mg unit 4 mg unit 5 mg unit
    Component formula formula formula formula
    Hydrogenated 176 176 176 176
    vegetable oil, type II,
    (Akopol E)
    Cocoa, alkalized 198 197 192 191
    Aspartame 2.4 2.4 2.4 2.4
    Sodium carbonate 15 20 30 40
    Lecithin 4 4 4 4
    Nicotine hydrogen 3.1 6.2 12.3 15.4
    tartrate,
    (corresponding to 1 2 4 5
    nicotine base, mg)
  • B. Nicotine Free Base [0252]
    1 mg unit 2 mg unit 4 mg unit 5 mg unit
    Component formula formula formula formula
    Hydrogenated 176 176 176 176
    vegetable oil, type II,
    (Akopol E)
    Cocoa, alkalized 198 197 192 191
    Aspartame 2.4 2.4 2.4 2.4
    Sodium carbonate 15 15 20 20
    Lecithin 4 4 4 4
    Nicotine free base 1 2 4 5
  • Example 5 Manufacture of Cores
  • This example describes without limiting the invention the manufacture of different cores according to the invention. [0253]
  • Objective [0254]
  • The objective of this example is to provide a core suitable for a chewing gum product according to the invention. The nicotine is incorporated as the free base (NFB), nicotine β-cyclodextrin complex (NCC), nicotine hydrogen tartrate (NHT) or as a nicotine resin complex (NRC). The amount of nicotine in each fomula unit, i.e., per tablett core, is 1, 2, 4, or 6 mg. [0255]
  • Principle [0256]
  • The core is formed by a mixing, rolling and scoring process or by a compression process. [0257]
  • Composition of the Cores [0258]
  • A. Manufactured by Tablet Compression Process. [0259]
    6 mg 4 mg 2 mg 1 mg
    unit formula unit formula unit formula unit formula
    (mg) (mg) (mg) (mg)
    Active ingredients
    Nicotine resin complex 20% 30 20 10 5
    Other ingredients
    Chewing gum base for 500 500 500 500
    compressiona
    Xylitol 191 211 221 226
    Sorbitol 100 100 100 100
    Encapsulated peppermint oil 100 100 100 100
    Sodium carbonate anhydr. 40 30 20 10
    Sodium bicarbonate 10 20
    Magnesium stearate 15 15 15 15
    Talcum 15 15 15 15
    Magnesium oxide 5 5 5 5
    Acesulfame K 2 2 2 2
    Aspartame 2 2 2 2
  • B. Manufactured by Mixing Rolling and Scoring [0260]
    6 mg 4 mg 2 mg 1 mg
    Unit formula Unit formula Unit formula Unit formula
    (mg) (mg) (mg) (mg)
    Active ingredients
    Nicotine β-cyclodextrin complex 52.2 34.8 17.4 8.7
    11.5%
    Other ingredients
    Chewing gum basea 650 650 650 650
    Xylitol 233 250 268 276
    Peppermint oil 30 30 30 30
    Sodium carbonate anhydr. 30 25 20 20
    Sodium bicarbonate 5 10 10
    Acesulfame K 2 2 2 2
    Levomenthol 2 2 2 2
    Magnesium oxide 1 1 1 1
  • C. Manufactured by Mixing Rolling and Scoring [0261]
    6 mg Unit 4 mg Unit 2 mg Unit 1 mg Unit
    formula formula formula formula
    (mg) (mg) (mg) (mg)
    Active ingredients
    Nicotine free base 6 4 2 1
    Other ingredients
    Chewing gum basea 620 620 620 620
    Xylitol 308 310 312 313
    Peppermint oil 30 30 30 30
    Sodium carbonate 30 25 20 10
    anhydr.
    Sodium bicarbonate 5 10 20
    Acesulfame K 2 2 2 2
    Levomenthol 2 2 2 2
    Magnesium oxide 2 2 2 2
  • D. Manufactured by Mixing Rolling and Scoring [0262]
    6 mg Unit 4 mg 2 mg Unit 1 mg
    formula Unit formula formula Unit formula
    (mg) (mg) (mg) (mg)
    Active ingredients
    Nicotine hydrogen 18.5 12.3 6.2 3.1
    tartrate
    Other ingredients
    Chewing gum basea 660 660 660 660
    Xylitol 246 263 269 272
    Fruit flavour 30 30 30 30
    Sodium carbonate 40 30 20 10
    anhydr.
    Sodium bicarbonate 10 20
    Acesulfame K 2 2 2 2
    Aspartame 2 2 2 2
    Magnesium oxide 1 1 1 1
  • E. Manufactured by Mixing Rolling and Scoring [0263]
    6 mg 4 mg 2 mg 1 mg
    Unit formula Unit formula Unit formula Unit formula
    (mg) (mg) (mg) (mg)
    Active ingredients
    Nicotine resin complex 20% 30 20 10 5
    Other ingredients
    Chewing gum basea 660 660 660 660
    Xylitol 235 255 265 270
    Peppermint oil 30 30 30 30
    Sodium carbonate anhydr. 40 30 20 10
    Sodium bicarbonate 10 20
    Acesulfame K 2 2 2 2
    Levomenthol 2 2 2 2
    Magnesium oxide 1 1 1 1
  • Procedures [0264]
  • I) Mixing, Rolling and Scoring [0265]
  • Mixing, rolling and scoring is done by a conventional procedure. Double sigma blade mixers are used for mixing the gum base with the other components of the formulation. The gum base is softened in the mixer. By heat (from the heating jacket) and mixing, the gum base becomes plastic. So, the softened base is mixed with the liquid components, e.g., flavours, liquid, sorbitol and glycerol, when used and the solid materials, e.g., nicotine in any form, buffer, bulk sweetener, colour) as a powder mixture. The warm mass is discharged from the mixer in form of loaves stacked on trays on a truck and stored in a conditioned area until the next step starts. This is to cool the gum. [0266]
  • After this, the rolling and scoring takes place. The gum is extruded into a thick sheet, which is rolled by multiple sets of calender rolls to the correct thickness. The scoring rolls, usually two sets, cut into the correct size. [0267]
  • The sheets are then transferred to a conditioned area on trays, where the sheets are cooled to make them brittle enough to be broken. The conditioned gum sheets are then passed through a breaker, which is a rotating drum that parts the sheets into separate pieces of gum along the scores. [0268]
  • At a sorting stage deformed gums are sorted away. The accepted gums are passed through a metal detector. [0269]
  • II) Compression [0270]
  • Chewing gums produced by compression (usually being a dry method), i.e., tabletted gums are made out of a special gum base. High velocity mixers can be used for granulation to give correctly sized particles of the mixture. This mixture is then compressed in a tablet machine. [0271]
  • At a sorting stage deformed gums are sorted away. The accepted gums are passed through a metal detector. [0272]
  • All publications and patent documents cited above are hereby incorporated by reference in their entirety for all purposes to the same extent as if each were so individually denoted. [0273]

Claims (66)

What is claimed:
1. A coated chewing gum product comprising at least one buffered or non-buffered chewing gum core; at least one of nicotine in any form or a nicotine mimicking agent, at least one coating layer and optionally one or more other additive(s), wherein said coating layer is buffered.
2. The product according to claim 1, wherein the at least one chewing gum core is buffered.
3. The product according to claim 1, wherein the nicotine in any form is a part of the at least one coating layer or at least one of the at least one coating layers.
4. The product according to claim 1, wherein the nicotine in any form is a part of the chewing gum core or at least one of the chewing gum cores.
5. The product according to claim 1, wherein the at least one coating layer is buffered and upon administration of the gum to a subject the pH of the saliva of the subject is increased by 0.3-4 pH units.
6. The product according to claim 5, wherein the at least one coating layer is buffered and upon administration of the gum to a subject the pH of the saliva of the subject is increased by 0.5-2 pH units.
7. The product according to claim 1 comprising nicotine in any form and a nicotine mimicking agent.
8. The product according to claim 1, wherein the at least one coating layer is buffered by the use of a buffer selected from the group consisting of a carbonate, glycinate, phosphate, glycerophosphate, acetate, gluconate or citrate of an alkali metal, and mixtures thereof, whereby optionally the buffer is microencapsulated, and wherein the optional buffering of the at least one chewing gum core is obtained by the use of a buffer selected from the group consisting of a carbonate, glycinate, phosphate, glycerophosphate, acetate, gluconate or citrate of an alkali metal, and mixtures thereof.
9. The product according to claim 8 wherein the carbonate is monocarbonate, bicarbonate or sesquicarbonate and the alkali metal is potassium, sodium, or ammonium.
10. The product according to claim 1, wherein the nicotine in any form is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, a nicotine inclusion complex or nicotine in any non-covalent binding, and mixtures thereof.
11. The product accord to claim 10 wherein the nicotine derivative is a nicotine cation exchanger and the nicotine in any non-covalent binding is nicotine bound to zeolites, nicotine bound to cellulose or nicotine bound to starch microspheres.
12. The product according to claim 10, wherein the nicotine inclusion complex is a cyclodextrin complex.
13. The product according to claim 12, wherein the cyclodextrin complex is β-cyclodextrin.
14. The product according to claim 11, wherein the nicotine cation exchanger is a polyacrylate cation exchanger.
15. The product according to claim 10, wherein the nicotine salt is a salt formed with tartrate, citrate or malate.
16. The product according to claim 1, wherein the nicotine in any form is present in an amount of 0.05-10 mg calculated as the free base form of nicotine per piece coated chewing gum product.
17. The product according to claim 16, wherein the nicotine in any form is present in an amount of 0.5-6 mg calculated as the free base form of nicotine per piece coated chewing gum product.
18. The product according to claim 17, wherein the nicotine in any form is present in an amount of 2-5 mg calculated as the free base form of nicotine per piece coated chewing gum product.
19. The product according to claim 3, wherein at least one coating layer comprises nicotine in any form in an amount of 0-10 mg calculated as the free base form of nicotine.
20. The product according to claim 19, wherein at least one coating layer comprises nicotine in any form in an amount of 0.2-6 mg calculated as the free base form of nicotine.
21. The product according to claim 20, wherein at least one coating layer comprises nicotine in any form in an amount of 0.5-5 mg calculated as the free base form of nicotine.
22. The product according to claim 1, wherein the nicotine mimicking agent is an agent with acrid burning taste.
23. The product according to claim 22, wherein the nicotine mimicking agent is capsaicin, piperine, zingerone or mixture thereof.
24. The product according to claim 1, wherein the optional one or more additive is selected from the group consisting of stabilisers, softeners, thickening agents, emulsifiers, glidants, lubricants, sweeteners, flavours, aromatics, enhancers, colouring agents, vitamins, minerals, and mixtures thereof.
25. The product according to claim 24 wherein the stabilizer is a preservative.
26. The product according to claim 25 wherein the preservative is an antioxidant.
27. The product according to claim 3, wherein in the coating, the nicotine and the buffer are in separate layers.
28. The product according to claim 27 wherein said layers are separated by a moisture barrier, said moisture barrier comprising substances selected from the group consisting of ethylcellulose, hydroxypropyl methylcellulose, polymethacrylates and combinations thereof.
29. The product of claim 28 wherein the nicotine is in the form of nicotine hydrogen tartrate and said moisture barrier further comprises at least one plasticizer or hydrophobic lipid-based film.
30. The product of claim 28 wherein the nicotine is in the form of nicotine hydrogen tartrate and said moisture barrier further comprises one or more plasticizers and hydrophobic lipid-based films.
31. The product of claim 29 wherein the lipid-based film comprises stearic acid.
32. A method for delivering nicotine in any form to a subject comprising the steps of
a) administering to a subject a coated chewing gum product according to claim 1 into the oral cavity of the subject, and
b) allowing the nicotine in any form in the coated chewing gum product to be released in the saliva in the oral cavity and absorbed into the systemic circulation of the subject.
33. The method according to claim 32, wherein said administration results in a tmax of nicotine in venous blood of the subject after about 5-20 minutes.
34. The method according to claim 32, wherein said nicotine in any form is a part of the at least one coating layer and said nicotine is released from the at least one coating layer and absorbed, resulting in a tmax of nicotine in venous blood of the subject after about 3-15 minutes.
35. The method according to claim 32, further comprising the step of
c) administering the nicotine in any form in a sustained way over a period of time to the subject.
36. The method according to claim 35, wherein the period of time is at least 10, 20, 30, 40, 50 or 60 minutes.
37. A method for obtaining reduction of the urge to use tobacco containing material, comprising the steps of
a) replacing at least partly the tobacco containing material with a coated chewing gum produt according to claim 1,
b) administering said coated chewing gum product into the oral cavity of the subject, and
c) allowing the nicotine in any form in the coated chewing gum product to be released in the saliva in the oral cavity and absorbed by the subject.
38. The method according to claim 37 wherein said method reduces the urge to smoke, provides a sense of smoking satisfaction without smoking or combinations thereof.
39. The method according to claim 37, wherein said administration results in a tmax of nicotine in venous blood of the subject after about 5-20 minutes.
40. The method according to claim 37, wherein said nicotine in any form is a part of the at least one coating layer and said nicotine is released from the at least one coating layer and absorbed, resulting in a tmax of nicotine in venous blood of the subject after about 3-15 minutes.
41. The method according to claim 37, further comprising the steps of administering the nicotine in any form in a sustained way over a period of time to the subject.
42. The method according to claim 41, wherein the period of time is at least 10, 20, 30, 40, 50 or 60 minutes.
43. The method according to claim 37, wherein said method is performed in combination with at least one other method for obtaining reduction of the urge to smoke or use tobacco.
44. A system for delivering nicotine in any form to a subject, comprising a coated chewing gum product according to claim 1 and at least one other means or method for obtaining reduction of the urge to smoke or use of tobacco.
45. The system according to claim 44, wherein the at least one other means or method is a concomitant or concurrent means or method selected from the group consisting of administration through mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets, parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods, and transmucosal methods.
46. The system according to claim 45, wherein the at least other means or method comprises administration of nicotine.
47. A system for obtaining reduction of the urge to smoke or use of tobacco or for providing a sense of smoking satisfaction without smoking comprising a coated chewing gum product according to claim 1 and at least one other means or method for obtaining reduction of the urge to smoke or use of tobacco.
48. The system according to claim 47, wherein the at least one other means or method is a concomitant or concurrent means or method selected from the group consisting of administration through mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets, parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods, and transmucosal methods.
49. The system according to claim 48, wherein the at least other means or method comprises administration of nicotine.
50. A method for producing a coated chewing gum product according to claim 1, comprising the steps of
a) providing at least one chewing gum core,
b) providing nicotine in any form,
c) providing at least one coating that is buffered,
d) adding the nicotine in any form to the at least one of the chewing gum core or the at least one coating, and
e) coating the at least one chewing gum core with at least one layer of the at least one buffered coating layer.
51. The method of claim 50 wherein said chewing gum core comprises nicotine.
52. The method according to claim 50, further comprising the steps of
f) buffering the at least one chewing gum core,
g) providing at least one coating layer not being buffered, and optionally
h) adding the nicotine in any form to at least one of said at least one coating layer not being buffered, and optionally
i) providing the nicotine in the coating and the buffer in the coating in separate layers, preferably separated by a moisture barrier.
53. The method according to claim 50, further comprising the steps of
f) buffering the at least one chewing gum core, or
g) providing at least one coating layer not being buffered, and optionally
h) adding the nicotine in any form to at least one of said at least one coating layer not being buffered, and optionally
i) providing the nicotine in the coating and the buffer in the coating in separate layers, preferably separated by a moisture barrier.
54. The method according to claim 50, wherein the nicotine in any form is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, a nicotine inclusion complex or nicotine in any non-covalent binding, and mixtures thereof.
55. The method accord to claim 54 wherein the nicotine derivative is a nicotine cation exchanger and the nicotine in any non-covalent binding is nicotine bound to zeolites, nicotine bound to cellulose or nicotine bound to starch microspheres.
56. The method according to claim 50, wherein the at least one coating layer is buffered by the use of a buffer selected from the group consisting of a carbonate, glycinate, phosphate, glycerophosphate or citrate of an alkali metal, and mixtures thereof, wherein the at least one coating layer is buffered and upon administration of the gum to a subject the pH of the saliva of the subject is increased by 0.3-4 pH units.
57. The method according to claim 56, wherein the carbonate is bicarbonate or sesquicarbonate and the alkali metal is potassium, sodium, or ammonium.
58. The method according to claim 57, wherein the at least one coating layer is buffered and upon administration of the gum to a subject the pH of the saliva of the subject is increased by 0.5-2 pH units.
59. The method according to claim 50, wherein the provision of the at least one chewing gum core in step a) comprises the steps of
a1) providing a gum core dough,
a2) mixing, rolling and scoring; moulding; or extruding the gum dough.
60. The method according to claim 50, wherein the provision of the chewing gum core in step a) is obtained by direct compressing of the ingredients.
61. The method according to claim 50, wherein coating the at least one chewing gum core with at least one layer of the at least one buffered coating comprises the steps of film coating, or press coating, or sugar coating, or melt coating, or combinations thereof.
62. A chewing gum product according to claim 1 for use in therapy.
63. The product according to claim 62, wherein the therapy is treatment of a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, and ulcerous colitis.
64. The product according to claim 62, wherein the therapy is treatment of post-smoking-cessation weight control.
65. A method of treating a disease selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome and ulcerous colitis comprising the steps of administering a chewing gum product of claim 1 to a subject.
66. A method of post-smoking-cessation weight control comprising the steps of administering a chewing gum product of claim 1 to a subject.
US10/481,053 2001-06-20 2002-06-14 Coated nicotine-containing chewing gum, manufacture and use thereof Abandoned US20040194793A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/249,619 US20120017924A1 (en) 2001-06-20 2011-09-30 Coated nicotine-containing chewing gum, manufacture and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102197-1 2001-06-20
SE0102197A SE0102197D0 (en) 2001-06-20 2001-06-20 New product and use and manufacture thereof
PCT/SE2002/001158 WO2002102357A1 (en) 2001-06-20 2002-06-14 A coated nicotine-containing chewing gum, manufacture and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/249,619 Continuation US20120017924A1 (en) 2001-06-20 2011-09-30 Coated nicotine-containing chewing gum, manufacture and use thereof

Publications (1)

Publication Number Publication Date
US20040194793A1 true US20040194793A1 (en) 2004-10-07

Family

ID=20284551

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/481,053 Abandoned US20040194793A1 (en) 2001-06-20 2002-06-14 Coated nicotine-containing chewing gum, manufacture and use thereof
US13/249,619 Abandoned US20120017924A1 (en) 2001-06-20 2011-09-30 Coated nicotine-containing chewing gum, manufacture and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/249,619 Abandoned US20120017924A1 (en) 2001-06-20 2011-09-30 Coated nicotine-containing chewing gum, manufacture and use thereof

Country Status (19)

Country Link
US (2) US20040194793A1 (en)
EP (1) EP1404306B1 (en)
JP (2) JP4571402B2 (en)
AR (1) AR034527A1 (en)
AT (1) ATE485034T1 (en)
AU (1) AU2002345454B2 (en)
BR (1) BR0210342A (en)
CA (1) CA2449298C (en)
CZ (1) CZ20033458A3 (en)
DE (1) DE60238054D1 (en)
DK (1) DK1404306T3 (en)
ES (1) ES2352681T3 (en)
IL (2) IL159425A0 (en)
MX (1) MXPA03011557A (en)
NZ (1) NZ529780A (en)
RU (1) RU2291688C2 (en)
SE (1) SE0102197D0 (en)
WO (1) WO2002102357A1 (en)
ZA (1) ZA200309204B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275344A1 (en) * 2005-05-18 2006-12-07 Seema Mody Flavoring of drug-containing chewing gums
US20070071710A1 (en) * 2005-09-23 2007-03-29 Chanel Parfums Beaute Extract of vanilla planifolia
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20080260825A1 (en) * 2007-04-02 2008-10-23 Maryka Quik Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US20090196834A1 (en) * 2004-06-29 2009-08-06 Carsten Andersen Tobacco alkaloid releasing chewing gum
WO2009141321A2 (en) * 2008-05-21 2009-11-26 Novartis Ag Tablettable chewing gums
US20100061940A1 (en) * 2006-03-16 2010-03-11 Niconovum Ab Chewing Gum Compositions Providing Rapid Release of Nicotine
US20100260690A1 (en) * 2007-09-18 2010-10-14 Arne Kristensen Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
US20110214681A1 (en) * 2008-09-17 2011-09-08 Niconovum Ab Process for preparing snuff composition
WO2011139684A2 (en) 2010-04-28 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
WO2011139811A1 (en) 2010-05-07 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
US20110318391A1 (en) * 2010-06-28 2011-12-29 Fuisz Richard C Bioactive Dose Having Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive
WO2013059592A1 (en) 2011-10-21 2013-04-25 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US20140261505A1 (en) * 2011-10-19 2014-09-18 Vivi Bjerre Jorgensen Nicotine Chewing Gum With Improved Utilization Of Nicotine
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
WO2017098443A1 (en) 2015-12-10 2017-06-15 Niconovum Usa, Inc. Protein-enriched therapeutic composition of a nicotinic compound
US9700525B2 (en) 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
US9744128B2 (en) * 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
US10130120B2 (en) 2013-03-15 2018-11-20 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
CN108991596A (en) * 2018-10-11 2018-12-14 玉溪开元金蓝生物科技有限责任公司 Compound Yunnan olive additive, preparation method and its application on cigarette filter rod
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US10258738B2 (en) 2004-09-13 2019-04-16 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CN110367592A (en) * 2013-07-19 2019-10-25 奥驰亚客户服务有限责任公司 The liquid aerosol formulations of electrical smoking utensil
WO2019239356A1 (en) 2018-06-15 2019-12-19 R. J. Reynolds Tobacco Company Purification of nicotine
US10653686B2 (en) 2011-07-06 2020-05-19 Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US10716764B2 (en) 2003-10-27 2020-07-21 Morningside Venture Investments Limited Transdermal drug delivery method and system
EP3445344B1 (en) 2016-04-21 2020-08-19 Fertin Pharma A/S Nicotine delivery product, related uses and oral dosage forms, and methods of production
CN112367978A (en) * 2018-07-13 2021-02-12 麦克内尔股份公司 Chewing gum comprising nicotine
US20210045430A1 (en) * 2008-12-19 2021-02-18 U.S. Smokeless Tobacco Company Llc Tobacco granules and method of producing tobacco granules
US11077089B2 (en) 2016-06-22 2021-08-03 Per Os Biosciences, Llc Oral compositions delivering therapeutically effective amounts of cannabinoids
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CN114945359A (en) * 2020-01-15 2022-08-26 麦克内尔股份公司 Chewing gum products and methods of manufacture
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1617823T1 (en) * 2003-01-24 2019-07-31 Nicachet Ab A pouch comprising a nicotine composition for transmucosal delivery
SE0302947D0 (en) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
EP1797769A3 (en) * 2003-02-04 2012-03-07 Gumlink A/S Compressed chewing gum tablet
EP1449525A1 (en) * 2003-02-20 2004-08-25 Cross Chem Llc chewing gum in the form of multi-layer tablets
WO2006020686A1 (en) * 2004-08-11 2006-02-23 Cadbury Adams Usa Llc Warming compositions and delivery systems therefor
WO2006037319A1 (en) 2004-10-08 2006-04-13 Gumlink A/S Confectionery product
US8524196B2 (en) 2004-11-30 2013-09-03 Fertin Pharma A/S Method of providing fast relief to a user of a nicotine chewing gum
US8024911B2 (en) 2006-02-16 2011-09-27 Mcneil Ab Method for blister packing
US20070269386A1 (en) 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
AU2012241150B2 (en) * 2006-07-21 2015-04-16 Jsrnti, Llc Medicinal delivery system and related methods
BRPI0808122A2 (en) * 2007-02-26 2014-06-17 Revolymer Ltd Medical Chewing Gum
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
JP2009102287A (en) * 2007-10-19 2009-05-14 Seiji Sakao Hot red pepper for smoking cessation
WO2009080021A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
EP2229156B1 (en) 2007-12-20 2016-11-09 Fertin Pharma A/S Chewing gum tablet and method of dosing pharmaceutically active ingredients in such chewing gum tablet
DK2229158T3 (en) * 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
AR071420A1 (en) 2008-05-01 2010-06-16 Smithkline Beecham Corp COMPOSITION OF PILL FOR ORAL SHOOTING THAT INCLUDES AN ACTIVE PRINCIPLE OF NICOTINE AND PROCEDURE FOR MANUFACTURING IT
EP2282645B1 (en) 2008-05-26 2015-04-15 Fertin Pharma A/S Flavor impregnation of a chewing gum core
CA2737307A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
US8506936B2 (en) * 2008-11-25 2013-08-13 Watson Laboratories, Inc. Stabilized nicotine chewing gum
EP2373179B1 (en) 2008-12-19 2018-08-01 Fertin Pharma A/S Multi-part kit comprising a chewing gum and further a flavor containing formulation
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
WO2010145653A1 (en) * 2009-06-19 2010-12-23 Fertin Pharma A/S Buffered gum base for high ph release
RU2417095C1 (en) * 2010-02-12 2011-04-27 Александр Ицхокович Кашлинский "curimalo" ("cm") product reducing craving for smoking
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
CN103478893B (en) * 2013-09-09 2016-02-10 湖南中烟工业有限责任公司 The application of theanine in matrix masticatory pattern smoke-free tobacco product
US10426726B2 (en) 2014-04-08 2019-10-01 Fertin Pharma A/S Medical chewing gum
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
SE541358C2 (en) 2017-05-30 2019-08-13 Enorama Pharma Ab Nicotine-containing chewing gum compositions
RU2770035C1 (en) * 2018-05-17 2022-04-14 Фертин Фарма А/С Chewing gum in tablet form, suitable for active pharmaceutical ingredients
US11096895B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet suitable for active pharmaceutical ingredients
US11058633B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Disintegrating oral tablet suitable for active pharmaceutical ingredients
US11052047B2 (en) 2018-05-17 2021-07-06 Fertin Pharma A/S Oral tablet suitable for fast release of active pharmaceutical ingredients
US11135157B2 (en) 2018-05-17 2021-10-05 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the throat
US11096896B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
US11096894B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
US11058641B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Oral tablet for taste masking of active ingredients
US11090263B2 (en) 2018-05-22 2021-08-17 Fertin Pharma A/S Tableted chewing gum suitable for active pharmaceutical ingredients
US20190350858A1 (en) 2018-05-17 2019-11-21 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the gastrointestinal tract
EP4326097A1 (en) * 2021-04-22 2024-02-28 Nicoventures Trading Limited Oral compositions and methods of manufacture

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US3877468A (en) * 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3901248A (en) * 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US4579858A (en) * 1983-01-21 1986-04-01 Aktiebolaget Leo Smoking substitutes for nasal administration-I
US4920989A (en) * 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4967773A (en) * 1986-06-26 1990-11-06 Shaw Alec S W Nicotine containing lozenge
US5057328A (en) * 1988-11-14 1991-10-15 Warner-Lambert Company Food acid delivery systems containing polyvinyl acetate
US5154939A (en) * 1989-04-19 1992-10-13 Wm. Wrigley Jr. Company Use of salt to improve extrusion encapsulation of chewing gum ingredients
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5656255A (en) * 1992-01-03 1997-08-12 Pharmacia & Upjohn Ab Composition to help stop smoking
US5721257A (en) * 1993-08-04 1998-02-24 Pharmacia & Upjohn Ab Method and therapeutic system for smoking cessation
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US5939100A (en) * 1993-11-01 1999-08-17 Pharmacia And Upjohn Ab Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US5972974A (en) * 1993-02-02 1999-10-26 Pharmaco Behavioral Associates, Inc. Transdermal nicotine metabolites and human body weight
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
US6183775B1 (en) * 1996-05-13 2001-02-06 Novartis Consumer Health S.A. Buccal delivery system
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US6586023B1 (en) * 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366211A (en) 1981-09-21 1982-12-28 Westinghouse Electric Corp. Control of electrolyte fill to fuel cell stack
GB2289204B (en) 1994-04-21 1998-01-14 Williamson Research Limited A chewing gum for use as a nicotine substitute and slimming aid
EP0745380B1 (en) * 1995-05-11 2005-08-03 University Of Utah Research Foundation Tobacco substitute
CA2271889C (en) 1996-11-27 2004-01-27 Wm. Wrigley Jr. Company Method of controlling release of caffeine in chewing gum and gum produced thereby
WO2000035298A1 (en) * 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
EP1107730B1 (en) 1998-09-03 2008-03-12 Jsr Nti Llc Medicated chewing gum delivery system for nicotine
AU6412299A (en) 1998-10-08 2000-04-26 Biovail Technologies Limited Composition and method for medicated chewing gum delivery system
WO2000056281A1 (en) * 1999-03-22 2000-09-28 Atp Avant-Garde Technologies & Product Marketing & Licensing S.A. Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3877468A (en) * 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3901248A (en) * 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4579858A (en) * 1983-01-21 1986-04-01 Aktiebolaget Leo Smoking substitutes for nasal administration-I
US4920989A (en) * 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4967773A (en) * 1986-06-26 1990-11-06 Shaw Alec S W Nicotine containing lozenge
US5057328A (en) * 1988-11-14 1991-10-15 Warner-Lambert Company Food acid delivery systems containing polyvinyl acetate
US5154939A (en) * 1989-04-19 1992-10-13 Wm. Wrigley Jr. Company Use of salt to improve extrusion encapsulation of chewing gum ingredients
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
US5656255A (en) * 1992-01-03 1997-08-12 Pharmacia & Upjohn Ab Composition to help stop smoking
US6024097A (en) * 1992-02-20 2000-02-15 J Mom Trust Product for assisting a smoker in giving up the habit
US5972974A (en) * 1993-02-02 1999-10-26 Pharmaco Behavioral Associates, Inc. Transdermal nicotine metabolites and human body weight
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5721257A (en) * 1993-08-04 1998-02-24 Pharmacia & Upjohn Ab Method and therapeutic system for smoking cessation
US5939100A (en) * 1993-11-01 1999-08-17 Pharmacia And Upjohn Ab Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US6183775B1 (en) * 1996-05-13 2001-02-06 Novartis Consumer Health S.A. Buccal delivery system
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US6586023B1 (en) * 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
US10716764B2 (en) 2003-10-27 2020-07-21 Morningside Venture Investments Limited Transdermal drug delivery method and system
US8529875B2 (en) * 2004-06-29 2013-09-10 Fertin Pharma A/S Tobacco alkaloid releasing chewing gum
US20090196834A1 (en) * 2004-06-29 2009-08-06 Carsten Andersen Tobacco alkaloid releasing chewing gum
US8828361B2 (en) 2004-06-29 2014-09-09 Fertin Pharma A/S Tobacco alkaloid releasing chewing gum
US10258738B2 (en) 2004-09-13 2019-04-16 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US10258778B2 (en) 2004-09-13 2019-04-16 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US11471424B2 (en) 2004-09-13 2022-10-18 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8658200B2 (en) 2005-05-18 2014-02-25 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
AU2006247847B2 (en) * 2005-05-18 2011-05-26 Warner-Lambert Company Llc Flavoring of drug-containing chewing gums
US8323683B2 (en) * 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
US20060275344A1 (en) * 2005-05-18 2006-12-07 Seema Mody Flavoring of drug-containing chewing gums
US8709502B2 (en) * 2005-09-23 2014-04-29 Chanel Parfums Beaute Extract of Vanilla planifolia
US20070071710A1 (en) * 2005-09-23 2007-03-29 Chanel Parfums Beaute Extract of vanilla planifolia
US11547660B2 (en) 2006-03-16 2023-01-10 Niconovum Usa, Inc. Snuff composition
US11129792B2 (en) 2006-03-16 2021-09-28 Modoral Brands Inc. Snuff composition
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US10219999B2 (en) 2006-03-16 2019-03-05 Niconovum Usa, Inc. Snuff composition
US20100061940A1 (en) * 2006-03-16 2010-03-11 Niconovum Ab Chewing Gum Compositions Providing Rapid Release of Nicotine
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US10799449B2 (en) 2006-07-21 2020-10-13 Jsrnti, Llc Medicinal delivery system and related methods
US7718677B2 (en) 2007-04-02 2010-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
US20080260825A1 (en) * 2007-04-02 2008-10-23 Maryka Quik Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US20100158895A1 (en) * 2007-04-02 2010-06-24 Maryka Quik Methods and compositions for reduction of side effects of therapeutic treatments
US20110077276A1 (en) * 2007-04-02 2011-03-31 Maryka Quik Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US20100159004A1 (en) * 2007-04-02 2010-06-24 Maryka Quik Methods and compositions for reduction of side effects of therapeutic treatments
US20100196463A1 (en) * 2007-04-02 2010-08-05 Maryka Quik Methods and compositions for reduction of side effects of therapeutic treatments
US20100166735A1 (en) * 2007-04-02 2010-07-01 Maryka Quik Methods and compositions for reduction of side effects of therapeutic treatments
US20100260690A1 (en) * 2007-09-18 2010-10-14 Arne Kristensen Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
WO2009141321A2 (en) * 2008-05-21 2009-11-26 Novartis Ag Tablettable chewing gums
WO2009141321A3 (en) * 2008-05-21 2010-10-28 Novartis Ag Tablettable chewing gums comprising nicotine and a buffering agent
US9511021B2 (en) 2008-05-21 2016-12-06 Novartis, A.G. Tablettable chewing gums
US20110129517A1 (en) * 2008-05-21 2011-06-02 Novartis Ag Tablettable chewing gums
US9763929B2 (en) 2008-05-21 2017-09-19 Novartis, A.G. Tablettable chewing gums
US9700525B2 (en) 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
US20110214681A1 (en) * 2008-09-17 2011-09-08 Niconovum Ab Process for preparing snuff composition
US8833378B2 (en) 2008-09-17 2014-09-16 Niconovum Ab Process for preparing snuff composition
US20210045430A1 (en) * 2008-12-19 2021-02-18 U.S. Smokeless Tobacco Company Llc Tobacco granules and method of producing tobacco granules
WO2011139684A2 (en) 2010-04-28 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
EP3284467A1 (en) 2010-05-07 2018-02-21 Niconovum USA, Inc. Nicotine-containing pharmaceutical compositions
WO2011139811A1 (en) 2010-05-07 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
US20110318391A1 (en) * 2010-06-28 2011-12-29 Fuisz Richard C Bioactive Dose Having Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US10653686B2 (en) 2011-07-06 2020-05-19 Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US9357801B2 (en) * 2011-10-19 2016-06-07 Fertin Pharma A/S Nicotine chewing gum with improved utilization of nicotine
US20140261505A1 (en) * 2011-10-19 2014-09-18 Vivi Bjerre Jorgensen Nicotine Chewing Gum With Improved Utilization Of Nicotine
WO2013059592A1 (en) 2011-10-21 2013-04-25 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
EP3744313A1 (en) 2011-10-21 2020-12-02 Modoral Brands Inc. Excipients for nicotine-containing therapeutic compositions
US11925201B2 (en) 2013-03-15 2024-03-12 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
US10881134B2 (en) 2013-03-15 2021-01-05 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
US10130120B2 (en) 2013-03-15 2018-11-20 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
CN110367592A (en) * 2013-07-19 2019-10-25 奥驰亚客户服务有限责任公司 The liquid aerosol formulations of electrical smoking utensil
US11154497B2 (en) 2014-06-05 2021-10-26 Per Os Biosciences, Llc Method for manufacturing medicated chewing gum without cooling
US10463612B2 (en) 2014-06-05 2019-11-05 Per Os Biosciences Llc Method for manufacturing medicated chewing gum without cooling
US9744128B2 (en) * 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
US10232156B2 (en) 2015-01-28 2019-03-19 Chrono Therapeutics Inc. Drug delivery methods and systems
US11400266B2 (en) 2015-01-28 2022-08-02 Morningside Venture Investments Limited Drug delivery methods and systems
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
WO2017098443A1 (en) 2015-12-10 2017-06-15 Niconovum Usa, Inc. Protein-enriched therapeutic composition of a nicotinic compound
US11311623B2 (en) 2016-04-21 2022-04-26 Fertin Pharma A/S Nicotine delivery product, related uses and oral dosage forms, and methods of production
EP3445344B1 (en) 2016-04-21 2020-08-19 Fertin Pharma A/S Nicotine delivery product, related uses and oral dosage forms, and methods of production
US11077089B2 (en) 2016-06-22 2021-08-03 Per Os Biosciences, Llc Oral compositions delivering therapeutically effective amounts of cannabinoids
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2019239356A1 (en) 2018-06-15 2019-12-19 R. J. Reynolds Tobacco Company Purification of nicotine
CN112367978A (en) * 2018-07-13 2021-02-12 麦克内尔股份公司 Chewing gum comprising nicotine
CN108991596A (en) * 2018-10-11 2018-12-14 玉溪开元金蓝生物科技有限责任公司 Compound Yunnan olive additive, preparation method and its application on cigarette filter rod
CN114945359A (en) * 2020-01-15 2022-08-26 麦克内尔股份公司 Chewing gum products and methods of manufacture

Also Published As

Publication number Publication date
RU2003137595A (en) 2005-02-10
NZ529780A (en) 2006-04-28
IL159425A (en) 2006-12-10
DK1404306T3 (en) 2011-01-24
SE0102197D0 (en) 2001-06-20
MXPA03011557A (en) 2004-03-18
EP1404306A1 (en) 2004-04-07
JP2010070564A (en) 2010-04-02
BR0210342A (en) 2004-07-13
DE60238054D1 (en) 2010-12-02
ATE485034T1 (en) 2010-11-15
WO2002102357A1 (en) 2002-12-27
IL159425A0 (en) 2004-06-01
CA2449298C (en) 2011-08-02
ES2352681T3 (en) 2011-02-22
EP1404306B1 (en) 2010-10-20
JP4571402B2 (en) 2010-10-27
US20120017924A1 (en) 2012-01-26
RU2291688C2 (en) 2007-01-20
JP2005500296A (en) 2005-01-06
AU2002345454B2 (en) 2006-07-20
AR034527A1 (en) 2004-02-25
ZA200309204B (en) 2005-02-23
CZ20033458A3 (en) 2004-05-12
CA2449298A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
AU2002345454B2 (en) A coated nicotine-containing chewing gum, manufacture and use thereof
CA2652500C (en) Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
AU2007250588B2 (en) Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
US20080286341A1 (en) Buffered coated nicotine containing products
AU2002345454A1 (en) A coated nicotine-containing chewing gum, manufacture and use thereof
AU2008251095B2 (en) Oral nicotine formulation buffered with amino acid
WO2018219650A1 (en) Nicotine-containing chewing gum compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACIA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LINDELL, KATARINA;LINDBERG, NILS-OLOF;OLSSON, ROLAND;REEL/FRAME:015451/0395;SIGNING DATES FROM 20040130 TO 20040204

AS Assignment

Owner name: MCNEIL AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PHARMACIA AB;PFIZER HEALTH AB;REEL/FRAME:020217/0254;SIGNING DATES FROM 20000928 TO 20061201

Owner name: MCNEIL AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PHARMACIA AB;PFIZER HEALTH AB;SIGNING DATES FROM 20000928 TO 20061201;REEL/FRAME:020217/0254

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION